Essays on Physician Incentives and Pharmaceutical Outcomes in Asthmatic Children. by Chang, Jongwha
  
 
 
 
 
ESSAYS ON PHYSICIAN INCENTIVES AND PHARMACEUTICAL 
OUTCOMES IN ASTHMATIC CHILDREN 
 
 
 
by 
 
 
 
Jongwha Chang 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
 (Social and Administrative Sciences) 
in The University of Michigan 
2012 
 
 
 
Doctoral Committee: 
 Associate Professor Rajesh Balkrishnan, Chair 
 Professor Richard P. Bagozzi 
Professor Gary L. Freed 
Associate Professor Steven R. Erickson 
 Associate Professor Lisa A. Prosser 
 
  
 
 
 
 
 
© Jongwha Chang 
 
All Rights Reserved 
 
2012 
  ii
DEDICATION   
 
This dissertation is dedicated to my dedicated wife (YoungSune June) and my family 
 
 
 
  iii
ACKNOWLEDGEMENTS 
 
There are many people whom I wish to express my deepest gratitude. First and 
foremost, none of this would have been possible without the constant help and guidance 
of my exceptional academic advisor and dissertation supervisor Dr. Rajesh Balkrishnan, 
who was there for me every step of the way with his constant encouragement and 
complete support of my academic career goals.  I feel very fortunate to have immensely 
benefitted from his excellent mentoring and sound advice for the last few years. Also, I 
would like to thank other members of dissertation committee – Drs. Richard Bagozzi, 
Steven Erickson, Gary Freed, and Lisa Prosser – who have given solid guidance, liberal 
support, and warm encouragement towards this dissertation research.  Professor Elliot 
Klayman always stands by me without any hesitation. I would like to extend faithful 
thanks to my friends at the Friday Tennis Club and other colleagues and fellow students 
for their great help and valuable support to this dissertation. I especially want to thank 
Isha Patel for her comprehensive support and friendship throughout the graduate 
program. Without all your help and support, I would not have made it so far. 
  iv
TABLE OF CONTENTS 
          
DEDICATION ........................................................................................................... ii 
ACKNOWLEDGEMENTS ....................................................................................... iii 
LIST OF FIGURES ................................................................................................... vi 
LIST OF TABLES ..................................................................................................... vii 
ABSTRACT ............................................................................................................... viii 
 
CHAPTER 
1 INTRODUCTION  ................................................................................................. 1 
  1.1 Study Rationale ............................................................................... 1 
  1.2 Significance of the Study ................................................................ 10 
  1.3 Study Objectives and Hypothesis ................................................... 13 
2 LITERATURE REVIEW ....................................................................................... 16 
  2.1 Prevalence of Asthma in U.S. ......................................................... 16 
  2.2 Economic Burden of Asthma Population ....................................... 18 
             2.3 Treatment Guidelines in Asthma .................................................... 19 
                     2.4 Pharmacotherapy in Asthma ........................................................... 22 
  2.5 Managed Care ................................................................................. 26 
  2.6 Managed Care Performance ............................................................ 28 
             2.7 Pay for Performance measures in managed care (P4P) .................. 29 
                     2.8 Theory and Conceptual Framework ................................................ 31 
3 RESEARCH METHODS  ...................................................................................... 39 
  3.1 Study Design ................................................................................... 39 
  3.2 Data Sources ................................................................................... 40 
  3.3 Study Population ............................................................................. 42 
  3.4 Covariates and Measures ................................................................ 44 
                     3.5 Statistical Analysis Plans ................................................................ 53 
                     3.6 Regression Diagnostics ................................................................... 57 
                     3.7 Conducting Overall Conclusion ...................................................... 60 
4 DISSERTATION MANUSCRIPT #1: ASSOCIATIONS BETWEEN PHYSICIAN 
FINANCIAL INCENTIVES AND PRESCRIBING OF ANTIASTHMATIC 
MEDICATIONS IN CHILDREN IN US OUPTIENT SETTINGS  .... 61 
5 DISSERTATION MANUSCRIPT #2: PHYSICIAN PAYMENT INCENTIVES AND 
ASSOCIATED HEALTHCARE UTILIZATION OUTCOMES IN 
MEDICAID ENROLLED ASTHMATIC CHILDREN  ...................... 81 
6 DISSERTATION MANUSCRIPT #3: COMPARISONS OF HEALTHCARE 
UTILIZATION OUTCOMES IN COMMERCIAL VERSUS MEDICAID-
ENROLLED ASTHMATIC CHILDREN  ........................................... 108            
7 OVERALL CONCLUSION ................................................................................... 135 
  7.1 Major Findings of Studies ............................................................... 135 
  v
  7.2 Implications of Study results for Medicaid Policymaking ............. 138 
  7.3 Test of Theoretical Model ............................................................... 139 
                     7.4 Limitations and Contributions ........................................................ 140 
                     7.5 Future Research .............................................................................. 143 
APPENDIX   .........................................................................................................   144 
BIBLIOGRAPHY ...................................................................................................... 145 
  vi
LIST OF FIGURES 
 
Figure 2.1 Eisenberg model of physician decision making .......................................       32 
Figure 2.2 Aday-Anderson Healthcare Utilization model & SPO model ..................       36 
Figure 2.3 Proposed Conceptual Model of this study ................................................       37 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  vii
LIST OF TABLES 
 
Table 1.1 Five Groups of Asthma Medications for Children .................................... 5 
Table 2.1 Components of Care, Key Clinical Activities and Action Steps ............... 20 
Table 2.2 Controller Therapeutic Drugs by Class and Common Name .................... 23 
Table 2.3 Reliever Therapeutic Drugs by Class and Common Name ....................... 24 
Table 3.1 Drug Classes in the Pharmacotherapy of Asthma ..................................... 44 
Table 3.2 Study Covariates for Manuscript 1  ........................................................... 46 
Table 3.3 Three-Level Risk Stratification of Asthma Severity ................................. 52 
Table 3.4 Analytical Framework and Study covariates for Manuscript 2 & 3  ......... 53 
Table 4.1 Drug Classes in the Pharmacotherapy of Asthma ..................................... 66 
Table 4.2 Study Covariates ........................................................................................ 68 
Table 4.3 Descriptive Statistics of the Children being seen for Asthma ................... 76 
Table 4.4 Odds ratios of anti-asthmatic medication use by logit model .................... 77 
Table 5.1 Three-Level Risk Stratification of Asthma Severity ................................. 91 
Table 5.2 Analytical Framework and Study Covariates for Chapter 5 ...................... 92 
Table 5.3 Patient Characteristics across the Health Plans ......................................... 101 
Table 5.4 Comparison of Predictors of Medication Adherence Rates across  
                Health Plans using Quantile Regression .................................................... 102 
Table 5.5 Comparison of Health Care Utilization across Health Plans using Logistic  
                and Poisson Regressions ............................................................................ 103 
Table 6.1 Three-Level Risk Stratification of Asthma Severity  ................................ 118 
Table 6.2 Analytical Framework and Study Covariates for Chapter 6 ...................... 118 
Table 6.3 Patient Characteristics across the Health Plans  ........................................ 129 
Table 6.4 Comparison of Medication Adherence Rates across Health Plans ............ 130 
Table 6.5 Comparison of Health Care Utilization across Health Plans ..................... 131 
 
 
 
 
 
 
 
 
  viii
 
 
ABSTRACT 
 
 
It is believed that health plans, reimbursement mechanisms and financial 
incentives led to health outcomes for health care utilization and medication adherence 
from pediatric populations. However, there is little empirical evidence about the effect of 
health plans, reimbursement mechanisms and financial incentives on asthmatic pediatric 
population.  
The first study examined how sociological factors including financial incentives 
influenced whether asthmatic children received a controller medication, a reliever 
medication or both. The 2007 National Ambulatory Medical Care Survey was used for 
this analysis. Compared with physicians who received lower financial incentives, 
physicians who received medium (39%, p<0.05) or higher (42%, p<0.01) financial 
incentives from payers were more likely to prescribe controller medication than reliever 
medication for children with asthma. 
            The second study examined associations between the type of health plan (fee for 
service vs. capitated) and utilization-based outcomes in asthmatic Medicaid children. 
Subjects were 6435 Medicaid enrolled asthmatic children who newly started asthma 
pharmacotherapy and were followed 12 months before and 12 month after the index anti-
asthmatic medication. Patient in capitated plans were associated with 77% more 
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hospitalizations and 34% increased incidence rates of emergency department visits, but 
42% fewer outpatient visits compared to those in FFS plans (all p<0.05). 
The third study examined the impact of the type of health plan (public vs. private) 
on health outcomes in pediatric asthmatic enrollees. Subjects were 11,027 asthmatic 
children (6,435 in Medicaid and 4,592 in a commercial HMO) who newly started asthma 
pharmacotherapy and were followed 12 months before after the index anti-asthmatic 
medication fill. Patients in Medicaid plans were also associated with 20% more inpatient 
hospitalizations and 50% increased odds of emergency department visits, but had 42% 
fewer outpatient visits compared to those in private plan (all p<0.05). 
In sum, the results of this study provide an insight to clinicians, policymakers and 
health service researchers in evaluating policies related to insurance coverage of essential 
medications in indigent children with asthma. This, in turn, could help understand 
important factors that impact health care financing, design strategies to improve asthma 
related care, and improve health outcomes for needy and poor children in the United 
States. 
 
  1
1  
 
CHAPTER 1 
INTRODUCTION 
1.1 Study Rationale 
Epidemiology of Asthma 
Asthma is one of the most commonly prevalent chronic medical conditions in US 
children, and indigent children (such as those covered by Medicaid) are at greater risk of 
poor asthma outcomes. Various demographic factors such as age, race, gender, ethnicity, 
socioeconomic status, weather, location of residence and surroundings have shown to 
play a role in asthma prevalence, morbidity and mortality.  (Holmes 2005; Mannino 
2002).  Asthma mortality increased by 3.4% every year from 1979 to 1998  amounting to 
about 2.2 deaths per 100,000 people  or about 4,200 deaths on a nationwide basis. 
(Akinbami and Schoendorf 2002; Casalino 2005). Recently, there has been a drop in the 
mortality rates due to successful implementation of clinical guidelines for asthma 
treatment (National Asthma Education and Prevention Program, 1997).  Amongst the 
pediatric asthmatic population, female children, teenage children and African American 
children bear a disproportionate burden of asthma. Asthma mortality among African 
American children is about four times higher compared to Caucasian children (Akinbami 
et al. 2009). Levels of healthcare utilization and decrease in work productivity (restricted 
activities or school absences) are some of the measures used to determine asthma 
morbidity in this population.  National estimates of these measures were available 
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systematically through patient surveys. According to the National Asthma Survey funded 
by the Centers for Disease Control and Prevention (CDC), as many as 45% had 1 missed 
school day due to asthma  (CDC, 2005).  On a national scale, this amounts to about 14 
million lost school days.   
            Missed school days are associated with considerable direct and indirect costs.  
Children who were frequently absent show poor performance at school and impact their 
parent’s work performance negatively since their parents might have to miss work when 
children decide to stay at home.  The CDC reported that in 1998, the total indirect costs 
due to missed school and work along with untimely deaths in the US cost over 53 billion 
dollars (CDC, 2005; American Lung Association, 2005). 
 
Asthma Burden on Poor Children 
Disproportionate asthma prevalence rates have been reported widely among poor 
children. Some indicators of this trend were higher rates of hospitalization and 
emergency room visits for asthma, lower utilization of pharmaceutical agents known to 
improve control of asthma, higher prevalence, higher severity of disease, and lower rates 
of utilization of asthma related primary care services among poor and minority children 
(Akinbami and Schoendorf 2002; Ash 2005; Dougherty 2005; Gold and Wright 2005; 
Krishnan 2001; Lieu et al. 2002; Weiss, Sullivan, and Lyttle 2000). This trend has been 
attributed to the nature of medical care system in U.S., its financing mechanisms, its 
concomitant impact on access to medical care and the individual characteristics of the 
population (Basu and Cooper 2000; Bindman 1995; Friedman 2001; Homer 1996; Lynch 
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1997). Poor children are more vulnerable to poor health in general because they are likely 
to have multiple risk factors (Aday 2001). Investigation of single risk factors is useful but 
it does not reflect the real-world scenario where risk factors are often clustered, e.g., low 
education and low income (Stevens et al. 2006). Previous research suggests that multiple 
risk factors may produce an additive impact on children's mental, physical, and social 
health and school performance (Starfield 2002; Stevens et al. 2006). This interactive 
influence has also been observed in the case of asthma (Accordini et al. 2006; Wood 
2002). 
It is also likely that this higher burden is related to a web of economic, 
educational, ethnic, and cultural characteristics particular to the individual or family. 
Besides these factors, contextual factors related to the geographic location in which the 
family resides, works, and attends school may also be contributing factors towards the 
disproportionate prevalence of asthma among poor and minority children. All of the 
factors above are tightly associated with poverty and race in America. The disparity in 
resources between the poor and non poor, characteristics of their neighborhood, and 
organizational features of the medical care system lead to differences in the prevalence 
and severity of poor asthmatic children and to differences in the medical and family 
management of pediatric asthma (Akinbami and Schoendorf 2002; Ash 2005; Chang et al. 
2011; Dougherty 2005; Gold and Wright 2005; Krishnan 2001; Lieu et al. 2002; Weiss et 
al. 2000). 
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Treatment and Medication in Asthmatic Children 
In the US, asthma affects millions of people leading to high morbidity and 
mortality and a lower quality of life.  The burden of asthma is high in children, especially 
poor children. In 1994, the aggregate direct cost of medical expenses borne by the society 
amounted to $6 billion (Weiss et al. 2000). Asthma led to indirect costs associated with 
missed school and work, thereby posing a financial burden on families, employers and 
the healthcare system. (Global Initiative for Asthma (GINA), 2006). 
Asthma guidelines have been used widely since many years and had been known 
to prevent the emergency department (ED) visits and inpatient hospital stays.  The 
process of asthma management is quite complicated. In order to assess asthma severity 
and persistence, it is necessary to perform symptomology assessments of patients 
regularly. Provision of patient education can help in successful asthma control since 
patients can practice self-management skills leading to regulation of pharmaceutical 
regimes, avoidance of attack triggering substances and behaviors and adherence to 
medication regimens.  However, there is lack of adherence to recommended treatment 
guidelines by both the physicians and patients.  (Global Initiative for Asthma (GINA), 
2006). 
Asthma medication is one of the key components for long-term asthma control. 
The National Asthma Education and Prevention Panel (NAEPP) report 2 (1997) 
emphatically recommended the use of steroid inhaler as the most effective long-term 
asthma control medication. Previous studies have shown the steroid inhalers when used 
daily, not only reduces asthma symptoms, severe exacerbations and use of quick-relief 
medications but also improves lung function, airway hyper responsiveness and FEV 
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(Cloutier et al. 2005; Cochrane 1999). The American Lung Association (2005) classified 
asthma medications for pediatric use under 5 different classes. These medications are 
prescribed as per their clinical use and are summarized in Table 1.1. 
Table 1.1 Five Groups of Asthma Medications for Children 
Type Effect 
Inhaled Bronchodilator Medications Inhaled bronchodilator medications are 
highly effective in opening airways narrowed 
by asthma. In fact, they are the most 
effective. In addition, they have few severe 
side effects when used in the recommended 
dose and frequency. They are available by 
both metered dose inhaler and nebulizer  
Anti-Inflammatory Medications Anti-inflammatory medications are 
recommended by the National Heart, Lung, 
and Blood Institute (NHLBI) expert panel for 
children with mild intermittent, moderate and 
severe asthma as the cornerstone for daily 
routine medical management. This panel 
recommends that one of these medications be 
given daily to control airway inflammation. 
They are considered safe and effective for 
long-term use. 
Systematic Bronchodilator Medications Systematic bronchodilator medications, 
principally theophylline, are effective but 
have more associated side effects that can be 
unpleasant although rarely life threatening. 
These medications are available in slow 
release tablets or capsules that are effective 
for 12 to 24 hours. These are especially 
helpful for nocturnal or night-time asthma. 
They are also used for daily control of 
asthma symptoms 
Systematic Corticosteroid Medications Systematic corticosteroid medications are 
highly effective in controlling asthma and 
reversing severe episodes. Unfortunately they 
can cause serious side effects when used for 
prolonged periods, and their use is therefore 
limited to severe episodes or chronic severe 
asthma which cannot be controlled with the 
first three groups of medications listed above.
Leukotriene Modifiers Leukotriene modifiers are a new class of oral 
anti-inflammatory asthma drugs recently 
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approved by the U.S. FDA. Sold under the 
names Accolate, Singulair, and Zyflo, these 
are also available by prescription. 
Adopted from American Lung Association (2005) 
 
Inhaled bronchodilators have few side effects and effectively open airways. Anti-
inflammatory medications are used for asthma with moderate severity and are 
recommended by NHLBI. Systematic corticosteroids effectively open airways but have 
many side effects if used for a long time. Leukotrine modifiers ware available by 
prescription only and are a relatively newer class of asthma medications (ALA, 2005). 
 
Health Care Utilization by Children 
Children in general use far fewer medical care resources than adults. In 2000, 
more than 25% of the general US population comprised of children aged 17 years or less 
but still represented only 18% of US hospitalizations. Average length of stay for children 
was only 3.3 days compared to 4.9 days for adults.  The average annual expenditure per 
child in 1999 was $1013 although the most costly 20% of children accounted for 81% of 
the total medical expenditures for children.  Children as a group accounted for only 
10.3% of all medical care expenditure in 1999 (Simpson et al. 2004). The trend 
throughout the 1990s showed that children in general had far fewer hospitalizations, 
fewer hospital outpatient visits, and fewer ED visits than adults.  There has been little or 
no change in the proportion of children with at least one office-based visit or at least one 
prescription filled in the US.  These indicators vary across population subgroups, 
insurance and health status and show some geographic variation by U.S. region. For 
example, inpatient discharges are lower for publicly insured children but ED utilization 
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have declined substantially for those publicly insured.  Between 1987 and 1999, the site 
of ambulatory care shifted from hospital outpatient and ED site toward office-based 
locations.  Medicaid covered 37.8% of all pediatric hospitalizations (54.5% private and 
5.1% uninsured) and length of stays were somewhat longer (3.7 days versus 3.1 days for 
private) in this insured population of Medicaid-enrolled children (Simpson et al. 2004). 
Among children in Medicaid managed care plans, several studies have found 
lower utilization of emergency rooms in managed care compared to fee for service (FFS) 
plans. One study however additionally found that Medicaid children in managed care 
presented with higher disease severity than those in FFS plans (Davidson 1992; Freund 
and Hurley 1995; Szilagyi 2000). The use of primary care services was seen to increase if 
the comparison plan was FFS (Freund and Hurley 1995; Friedman 2001) but if the 
Medicaid managed care reimbursement method was capitation, then some lowered use of 
primary care services was seen among children in Medicaid managed care plans (Kaye 
2005; Leibowitz 1992). 
A number of studies have looked at utilization of specialist services, referrals to 
specialists, choice of providers, and breadth of available services between various 
managed care types and traditional FFS plans.  Private insured children in managed care 
had no consistent difference in referrals and service use of medical specialist compared to 
children in private FFS plans although there was some evidence of restricted coverage for 
chronically ill children in MC plans (Szilagyi 2000).  However, among Medicaid 
managed care plans there was evidence of fewer special visits and more restricted 
coverage as compared to FFS Medicaid plans (Szilagyi 2000). 
  8
 According to a study by Hickson and colleagues, fee for service reimbursement 
received by physicians led to more scheduled physician visits among patients compared 
to physicians receiving reimbursement on a capitated basis. The same study also 
suggested that pediatricians belonging to fee for service plans that follow the guidelines 
suggested by the American Academy of Pediatrics are more likely to see patients for 
well-child care compared to physicians belonging to capitated plans because patients 
missed fewer recommended visits and fee for service physicians scheduled recommended 
visits. Fee for service physicians were also known to provide better continuity of care, 
attend to more patients and encourage fewer ED visits compared to physicians belonging 
to capitated plans (Pawaskar 2010). Medicaid uses capitation as a means to contain costs 
but they might not be cost effective in the long run. 
Managed Care Organizations (MCO) in Healthcare 
Managed care brought about a revolution in the US healthcare system in the 
1990s by significantly bringing down the healthcare spending throughout the nation. 
MCOs aim to improve asthma quality of care and healthcare utilization cost-effectively 
through provision of a) equal access to care using shared provider networks, b) case 
management using patient support and c) shared management expertise for all plans. Plan 
characteristics and services provided in both FFS and capitation programs under 
Medicaid might share dissimilarities with regards to certain services like patient cost 
sharing or transportation assistance. During recent years, enrollees have expressed 
dissatisfaction with some of the restrictive policies of managed care and have shown 
preference for the less restrictive Preferred Provider Organizations (PPOs). PPOs have 
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managed cost controls using their negotiation power with regards to reimbursement rates. 
The evidence-based quality of care provided by MCOs has shown inconclusive results 
and evidence about quality of care provided by other plans such as PPOs is largely absent 
in Medicaid-enrolled populations. The hypothesis that long term financial incentives by 
MCOs (through delivery of evidence based quality health care and promotion of 
preventive care)  outweigh short term incentives (through restricting utilization) lacks 
sufficient evidence (Dombkowski 2005; Donahue et al. 2000; Gavagan et al. 2010; 
Godard 2002; Karnick et al. 2007). This study will be amongst the first to examine the 
ramifications of managed care services on healthcare utilization, access / quality of 
pharmaceutical care and associated outcomes for both Medicaid and privately insured 
pediatric populations. 
Insurance Coverage in Medicaid Managed Care 
From its inception, the Medicaid program's costs have exceeded estimates 
(Freund and Hurley 1995; Gendo et al. 2003; Georgiou et al. 2003). The US congress 
authorized waivers to state Medicaid plans in 1981 that made it possible for states to 
experiment with managed care as a means to control costs (Stevens et al. 2006; Thomson 
et al. 2003).  States commonly implemented one of two types of Medicaid managed care 
plans: 1) Capitation (pre-paid) and 2) Fee-For-Service ((Kaye 2005)). Under the 
capitation or prepaid model, managed care organizations (MCOs) received payment on a 
capitated basis (fixed payment) to deliver healthcare to enrollees. The fees under 
capitation remained constant irrespective of the number of services used by individual 
enrollees during any particular month in a year. The MCOs who function as contractors 
  10
bear the either partial or full burden of financial risk by delivering healthcare services to 
the enrollees. The financial risk may or may not be passed on to the providers by MCOs. 
However, this will depend solely on the contract.  About 45% of the Medicaid managed 
care patients were enrolled under this model (Kaiser Family Foundation 2001). Fully-
capitated plans may actually pay all or some of their provider network on a FFS basis. 
Partially capitated plans allowed for some risk-sharing between the Medicaid agency and 
the MMC plans (Casalino 2005; Çelik et al. 2004; Gendo et al. 2003; Godard 2002; Gold 
and Wright 2005). Under the Fee-For-Service Primary Care Case Management (PCCM) 
model, primary care practitioners (PCPs) act as gatekeepers to determine the eligibility of 
services being provided to beneficiaries. The gatekeepers do not bear any burden of 
financial risk by delivering healthcare services to the plan enrollees. PCPs are paid on a 
fee-for-service basis and are also eligible for an additional fee per enrollee per month for 
fulfilling case management responsibility associated with each enrollee. PCCM requires 
beneficiaries to choose a PCP from an approved list of contracted physicians. The PCP 
receives a monthly fee for coordinating care and issuing referrals plus reimbursement via 
the usual FFS mechanism for medical services provided. 
1.2 Significance of the Study 
Managed care and financial incentives programs are putting limits on physicians’ 
autonomy in drug prescribing (Casalino 2005; Conrad 2004). As the services provided by 
physicians expand beyond a single managed care plan, physicians will have to develop 
skills for managing multiple formularies. The third party share of total outpatient 
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prescriptions is also increasing rapidly. In 2004, it was estimated that almost 61.4% of 
prescription costs were borne by third party payers (Jansson et al. 2007) . 
  Knowledge about incentives provided by the managed care plans to physicians 
can help in understanding physician prescribing behaviors.  Pay for Performance (P4P) 
focuses more on preventive care and maximizing gains in patient outcomes. Children 
have substantially different medication regimens than adults.  Additionally, conditions 
such as asthma are more prevalent in children. Thus one could potentially hypothesize 
that if P4P were to be focused on a younger population, there is more likelihood of 
greater returns over a lifetime.  Also, one of the P4P indicators for medication prescribing 
is more usage of controller medication for symptom management in a chronic condition 
like asthma.  There is likelihood of receipt of more incentives by the physician if he/she 
prescribes more controller medications used to control asthma as opposed to reliever 
medication which provides temporary relief to the patient. As far as disease severity is 
concerned, if asthma is controlled right from the childhood stage, there is a lower 
probability of increased asthma severity and deteriorated health due to the same in the 
adult stage. In addition, medication therapy for controlling asthma in children could be 
cost effective in the long run and could result in lower economic burden on the payer and 
society. 
Factors affecting medication adherence in asthmatic children have been 
extensively examined in previous literature. There is scarcity of research evaluating the 
impact of payment mechanisms or the type of health plan (capitated vs. FFS) on 
medication adherence in asthma. Some studies have looked at outcomes in asthmatic 
patients with public or private insurance (Jackson et al. 2003; Janson and Weiss 2004; 
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Karnick et al. 2007). Studies have also looked at the role of capitation on preventive care 
or diagnostic testing (Karnick et al. 2007; Rittenhouse and Robinson 2006) in asthma. 
Studies evaluating the differences in Medicaid FFS and capitation have examined 
individuals with mental health issues or special health needs like sickle cell disease. 
However, studies have not compared FFS and capitated payment mechanisms under 
managed care in asthmatic children. Also previous studies have only looked at changes in 
healthcare utilization and cost containment (Gendo et al. 2003; Georgiou et al. 2003; 
Ungar 2008). Poor quality of care and lower medication adherence can potentially harm 
asthmatic children’s health. Previous research did not explore the impact of the type of 
health plan on medication adherence behavior. This study was among the impact of 
capitated health plans vs. traditional FFS plans on the treatment of asthma in children. It 
can help policy makers design appropriate reimbursement policies that ensure effective 
allocation of scarce healthcare resources among vulnerable population. 
Previous literature lacks evidence about the effect of different health plans on the 
medication outcomes of children with asthma. None of the prior studies have focused 
only on asthmatic children in Medicaid; none have evaluated asthmatic children in 
Medicaid and privately insured children for the same period.  Thus, comprehensive 
concurrent information regarding Medicaid and commercial insurance related to asthma 
and relevant recent trends in health care utilization were needed.  
              Therefore, the results of our present study provide a unique insight to 
clinicians, policymakers and health service researchers with regards to examining 
policies related to coverage of essential medications in indigent children with chronic 
disease. It could also help in differentiating among medication outcomes and healthcare 
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utilization with respect to different payment mechanisms or health plans in children with 
asthma. This in turn can help understand the important factors that impact health care 
financing, design strategies to improve asthma related care, and improve health outcomes 
for needy and poor children. 
 
1.3 Study Objectives and Hypothesis 
The following objectives and hypothesis were addressed in the three manuscripts 
which will be elaborated in the Chapters 4, 5 and 6, respectively. Based on preliminary 
studies and the literature review, the specific objectives of this study were: 
 Objective 1: To determine the factors that may predict the prescribing of controller    
 medications in the pharmacotherapeutic management of asthma under the financial   
 incentive from P4P 
 H1: Financial incentives under the Capitated health plans will be associated with more  
 prescribing of controller medication compared to FFS plans in the asthmatic children of    
 Ambulatory care (Manuscript #1) 
  
Objective 2: To determine the association between medication adherence and   
 healthcare utilization in asthmatic Medicaid children controlling for other covariates. 
 H2: There will be difference in the patient characteristics between the type of health    
 plan (Capitated vs. FFS) in the asthmatic children (Manuscript #2) 
 H2a: Higher medication adherence will be associated with the lower likelihood of  
 Healthcare utilization in the asthmatic children in Medicaid (Manuscript #2) 
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 H2b: Capitated health plans will be associated with the decreased likelihood of   
 Healthcare utilizations such as hospitalization and emergency department visit   
 compared to FFS plans in the asthmatic children in Medicaid (Manuscript #2) 
 H2c: Capitated health plans will be associated with the higher medication adherence    
 compared to FFS plans in the asthmatic children in Medicaid (Manuscript #2) 
 
 Objective 3: To examine association between type of health plan and healthcare costs 
controlling for medication adherence, demographic, and other covariates 
 H3: There will be different healthcare costs between the types of health plan (Capitated   
 vs. FFS) in the asthmatic children (Manuscript #2) 
 
 Objective 4: To examine the likelihood of an inpatient hospitalization due to asthma   
 between publicly insured pediatric patients and privately insured patients from  
 MarketScan Claims  
 H4: The likelihood of an inpatient hospitalization due to asthma is higher among publicly   
 insured pediatric patients than a privately insured patient all else being equal 
(Manuscript #3) 
 
 Objective 5: To examine the likelihood of an emergency department encounter due to   
 asthma between publicly insured pediatric patients and privately insured patients from   
 MarketScan Claims   
 H5: The likelihood of an emergency department encounter due to asthma is higher   
 among publicly insured pediatric patients than a privately insured patients all else being  
  15
 equal (Manuscript #3) 
 
 Objective 6: To examine association between likelihood of health plan and healthcare   
 costs adjusting for medication adherence, demographic, and other covariates 
 H6: There will be different healthcare costs between the types of health plan (Private vs.   
 Public) in the asthmatic children (Manuscript #3) 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Prevalence of Asthma in U.S. 
Asthma is a chronic respiratory disease characterized by episodes or attacks of 
inflammation and narrowing of small airways in respiratory system. Asthma attacks can 
vary from mild to life-threatening and may involve shortness of breath, coughing, 
wheezing, chest pains or tightness, or a combination of these symptoms. Many factors 
like allergens, infections, exercise, abrupt changes in the weather, or exposure to airway 
irritants, such as a tobacco smoke can trigger an asthma attack (NCHS, 2005). 
Some of the most established measures of prevalence of asthma are Center for 
Diseases Control’s (CDC) Behavioral Risk Factor Surveillance Survey (BRFSS) and the 
National Health Interview Survey (NHIS) (CDC 2007; NCHS 2005). These surveys have 
the usual limitations associated with self-reported data like non-response bias, and low 
precision for state and sub-state estimates associated with surveys that used multistage 
sample selection with the goal of developing national estimates. Additionally, the BRFSS 
only surveys adults, and the NHIS have a relatively small sample of children that 
precludes state level estimation. A change in NHIS questionnaire language in 1997 
concerning asthma prevalence made comparisons to periods before and after that date 
problematic. Given these limitations, estimates of the lifetime prevalence of asthma 
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among adults have ranged from 10-12% over the past 6 years while current asthma for 
adults is generally reported at approximately 7-8% (Mannino 2002). National estimates 
suggest that lifetime asthma prevalence for children less than 18 was approximately 
12.5% with age specific prevalence of 7.5, 14, and 14.7 percent for children aged 0-4, 5-
11, and 12-17 respectively (CDC 2005). 
Another source for asthma prevalence data are local studies and surveys. These 
studies sometimes reported prevalence levels quite different from national estimates. For 
example, school-based studies of asthma in poor, low-income neighborhoods, reported 
life-time and 12-month prevalence as high as 24% of the student population (Andersen 
and Andersen 2005; Mvula et al. 2005). These large differences were probably due to the 
population studied and questionnaire design. 
Finally, administrative claims data have also been used to estimate prevalence of 
pediatric asthma. This source has the advantage of being available for state and sub-state 
geographies, specific populations of interest (e.g., Medicaid), and was usually free or 
inexpensive to obtain (Andersen and Andersen 2005; Buescher and Jones-Vessey 1999; 
Dombkowski 2005; Gillespie 2002; Lynd 2002; Macy et al. 2005; Piecoro 1999; Twiggs 
et al. 2002). Administrative claims data can be difficult to use and sometimes may not 
accurately reflect underlying clinical diagnosis condition (Piecoro 1999; Twiggs et al. 
2002). It may also not accurately reflect the population characteristics of the state or sub-
state geography of interest. For example, Medicaid data may reflect benefit utilization 
only by less affluent population and commercial health insurance policies may only 
reflect utilization by families with working age adults insured through their employers.  
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In spite of these limitations, claims data (particularly Medicaid claims and 
encounter data) are used frequently to assess asthma prevalence and to monitor 
utilization-based measures of quality. Asthma prevalence in pediatric Medicaid 
populations have been reported to range from 1.4 to 14.9% depending on the case 
definition of asthma, the age of the children, and whether the Medicaid plan was of the 
Fee-for-Service, Health Maintenance Organization, or Primary Care Case Management 
type ((Buescher and Jones-Vessey 1999; Dombkowski 2005; Lynd 2002; Piecoro 1999; 
Schatz et al. 2005; Smith, Rascati, and Barner 2005). 
 
2.2 Economic Burden of Asthma in the US Population 
The economic burden related to asthma is one of the highest when compared to 
other chronic conditions. Asthma medications share a majority of this burden 
contributing to almost 38%–89% of the total costs (Accordini et al. 2006; Çelik et al. 
2004; Cisternas et al. 2003; Gendo et al. 2003; Godard 2002; Jansson et al. 2007; Serra-
Batlles 1998; Ungar 1998; Ungar and Coyte 2001). When the asthmatic pediatric and 
adult populations were compared, the cost of asthma medications for children was higher 
($382.09 or 41.3% of total direct cost) and the cost of hospital care was higher in adults 
($928.28 or 46.5% of total direct cost) (Szilagyi 2000).  
Besides medications and hospital care, disease severity is another factor that 
contributes towards estimation of asthma economic burden. The cost distribution in 
asthmatic patients varies greatly with disease severity. A one year study showed that 
asthma patients with exacerbations shouldered 70% in medication costs and 10% in 
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hospital costs. On the other hand, asthma patients with exacerbations shouldered 28% in 
medication costs and 63% in hospital costs (Schwenkglenks et al. 2003). Asthma care 
behavior and asthma related costs varied with regards to differences in the perspective of 
patients, society and the government in a particular nation.  In some studies looking at the 
asthma related costs, it was found that hospital costs comprised the highest proportion of 
asthma costs in adults when analyzed from a societal perspective (Jansson et al. 2007; 
Johnson and Dinakar 2010) and in children when analyzed from a societal and 
government perspective respectively (Ungar 2008). However, when the same studies 
looked at asthma related costs from patient’s perspective, medication costs comprised to 
be the highest contributing factor (Ungar 2008). 
 
2.3 Treatment Guidelines in Asthma 
Pediatric asthma was associated with a heavy burden of morbidity in the US. In 
order to reduce this morbidity, there are evidence based guidelines in place for treating 
pediatric asthma. These guidelines have been made by the National Asthma Education 
and Prevention Program (NAEPP) in coordination with the National Heart, Lung, and 
Blood Institute (NHLBI) (National Asthma Education and Prevention Program, 2002). 
These asthma guidelines were a result of efforts of several researchers belonging to 
various clinical, academic, and governmental organizations. These guidelines were based 
on updated and most recent evidence available in the field (National Asthma Education 
and Prevention Program, 2002). The NAEPP was first established in 1989 and the first 
set of guidelines were released in 1991 (Williams et al., 2003). Later in 1997 and 2002, 
  20
two expert panel reports were released (National Asthma Education and Prevention 
Program, 1997b; National Asthma Education and Prevention Program, 2002).  The 
guidelines were classified into different components of care:  1) assessing and 
monitoring; 2) controlling factors leading to asthma; 3) pharmacotherapy; and 4) 
education for building partnerships to deliver care. Each of the components was linked to 
clinical activities and other activities associated with the NAEPP guidelines as listed in 
Table 2.1 Components of Care, Key Clinical Activities, and Action Steps. However the 
asthma guidelines were designed for long term asthma care as opposed to acute asthma 
care generally seen in ED patients or inpatients.  Table 2.1 presents a summary of the 
four components of care with associated clinical activities (Williams et al., 2003). 
Table 2.1 Components of Care, Key Clinical Activities, and Action Steps 
 
Components of 
Care 
Key Clinical 
Activities 
Action steps 
Assessment and 
monitoring 
Establish 
asthma 
diagnosis 
Establish a pattern of symptoms and history of 
recurrent episodes 
  Document reversible airflow using spirometry 
  Rule out other conditions 
 Classify 
severity of 
asthma 
Follow the NAEPP* classification system and 
recheck at every visit 
 Schedule 
routine follow-
up care 
See patients at least every 1-6 months 
according to severity 
  Perform spirometry at least every 1-2 years for 
the stable patient, more often for the unstable 
patient 
  Review medication use, care plan and self-
management skills at every visit 
 Assess for 
referral to 
specialty care 
Refer to specialty care when referral criteria are 
met 
Control of factors Recommend Determine exposures and sensitivities, 
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contributing to 
asthma severity 
measures to 
control asthma 
triggers 
including environmental and occupational 
triggers 
  Review ways to reduce exposure to allergens 
and irritants that provoke asthma symptoms 
  Discuss smoking avoidance with every patient 
who smokes or who is exposed to 
environmental tobacco smoke 
  Assess for EIB* if symptoms occur during 
exercise, and provide medication and advice to 
enable physical activity 
 Treat or prevent 
comorbid 
conditions 
Consider, particularly, rhinitis, sinusitis, 
GERD*, COPD* 
  Provide annual influenza vaccination for 
patients with persistent asthma 
Pharmacotherapy Prescribe 
medications 
according to 
severity 
Reduce inflammation in patients with persistent 
asthma with anti-inflammatory medications 
  Increase medications if necessary; decrease 
when possible 
  Provide appropriate medication delivery and 
monitoring devices 
  Recommend spacers, nebulizers, or both if 
needed and consider PFM* for patient with 
moderate to severe asthma or a history of 
severe exacerbations 
 Monitor use of 
Beta 2 – 
agonist drugs 
Reevaluate patients using more than one 
canister per month of short-acting beta 2 – 
agonist drug 
Education for 
partnership in care 
Develop a 
written asthma 
management 
plan 
Agree on therapy goals 
  Outline daily treatment and monitoring 
measures 
  Prepare an action plan to handle worsening 
symptoms/exacerbations 
 Provide routine 
education on 
patient self-
management 
Teach/review 
  How and why to take long-term control and 
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quick-relief medications 
  Correct technique for inhaler, spacer, PFM*, 
and nebulizer as indicated 
  Peak flow/symptom monitoring with patients 
when appropriate 
  Factors that worsen asthma and actions to take 
Acronyms: NAEPP National Asthma Education and Prevention Program; EIB exercise 
induced bronchoconstriction; GERD gastroesophageal reflux disease; COPD chronic 
obstructive pulmonary disease; PFM peak flow meter. 
 
Asthma treatment guidelines have been developed to measure the proposed 
outcomes of the MC industry (National Committee for Quality Assurance, 2000) as well 
as in concordance with the goals of Health People 2010, and the U.S. Department of 
Health and Human Services (DHHS) strategic plan for asthma (US Department of Health 
and Human Services, 2000; Williams et al., 2003; US Department of Health and Human 
Services Office of the Assistant Secretary for Planning, 2000). 
 
2.4 Pharmacotherapy in Asthma 
Therapeutic asthma drugs are summarized into four major types: 1) 
Bronchodilators, 2) Corticosteroids, 3) immunotherapy, and 4) anti-IgE antibodies in 
Table 4. Bronchodilators are available in long and short-acting formulations for opening 
constricted airways. They are also called rescue or reliever drugs. Corticosteroids are 
anti-inflammatory drugs that aid in preventing or decreasing the frequency of asthma 
attacks. They are also called controller drugs. Immunotherapy consists of allergy 
desensitization injections for desensitizing the body to allergens and anti-IgE monoclonal 
antibodies that prevent the immune system from attacking the allergens.  Among all the 
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therapeutic asthma drugs, corticosteroids are the most effective for treating asthma (Mayo 
Clinic Staff, 2006). These therapeutic classes maybe used separately or in combination 
depending on the desired action. For example, reliever drugs provide quick relief whereas 
controller drugs provide long-term control in asthma.  Also, many of the therapeutic 
drugs have different therapeutic classes and are available in different formulations like 
oral, inhaled, injectables and intravenous preparations. The dosage of the drugs is 
determined based on patient age and severity of the condition. Controller medications 
with their common names are summarized in Table 2.2. 
Table 2.2 Controller Therapeutic Drugs by Class and Common Name 
 
Therapeutic Class Common Names 
Combination Inhalers 
(ICA/LABA) 
Fluticasone 
Salmeterol 
Budesonide 
Formoterol 
  
Inhaled 
Corticosteroid (ICS) 
Beclomethasone 
CFC 
Beclomethasone 
HFA 
Budesonide 
DPI 
Flunisolide Fluticasone 
Inhaled 
Corticosteroid 
(ICS) 
Mometasone Triamcinolone 
Acetonide 
Ciclesonide 
 
 
Leukotriene 
Modifiers 
Montelukast Zafirlukast Zileuton Pranlukast 
Mast Cell Stabilizers Cromolyn, Sodium 
Cromoglycate 
Nedocromil 
/cromones 
  
Immunomodulators Omalizumab Anti-IgE   
Methylxanthines Theophylline    
Systemic 
Corticosteroids 
(Tablet or Syrup) 
Methylprednisolone Prednisolone Prednisone Hydrocortisone 
Theophylline SR     
 
Asthma reliever drugs and their common names appear in Table 2.3 (Mayo Clinic Staff, 
2006).  
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Table 2.3 Reliever Therapeutic Drugs by Class and Common Name 
 
Short-Acting Beta-2 
Agonists 
(SABA) 
Anticholinergics Short-Acting 
Theophylline 
Albuterol /Salbutamol Ipratropium Aminophylline 
Pirbuterol Ipratropium with 
Albuterol 
 
Bitolterol Ipratropium bromide  
Fenoterol Oxitropium bromide  
Levalbuterol   
Metaproterenol   
Terbutaline   
Epinephrine/adrenaline   
 
Stepwise treatment guidelines suggest that asthma attacks or triggers like exercise 
that lead to an asthma attack can be treated using a short-acting bronchodilator. In case of 
mild intermittent asthma characterized by severe but infrequent asthma attacks, the use of 
systemic corticosteroids along with short-acting bronchodilators is recommended.  
Increased use of reliever drugs such as short-acting beta2- agonists for more than 2 times 
a week or use more than 1 canister every month characterizes poorly controlled asthma 
(National Asthma Education and Prevention Program, 2002). Success of a proper asthma 
control program is associated with the appropriate use of reliever and controller asthma 
medications (Finkelstein 2002; Georgiou et al. 2003; Schatz et al. 2005; Schatz 2004; 
Simpson et al. 2004; Stanley J 2010).  
The next step includes recommendations for utilization of inhaled corticosteroids 
(ICS) only or along with long-acting bronchodilator drugs based on disease severity and 
the desired level of asthma control to be achieved. Many previous studies have provided 
evidence of reduction in an ED visit or IP stay due to the use of ICS drugs (Agertoft and 
Pedersen 2000; Hoekstra 2004; Jadad et al. 2000). 
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Overall the 27 asthma recommendations and guidelines could potentially lead to 
numerous physician responses while treating asthma. Some of the physician behaviors 
which are part of important clinical activities are summarized as follows: 1) accurately 
diagnosing and assessing asthma based on its severity, 2) recommending follow up on 
regular basis for evaluating disease condition, 3) providing complicated asthma self-
management information to children and care givers, 4) suggesting specialist referrals 
whenever necessary, 5) provide influenza vaccination, and 6) provide hand written 
asthma management plans as a resource for care givers and school personnel. On an 
average, a physician spent about 15 minutes with the patient (Mechanic 2001; Mechanic, 
McAlpine, and Rosenthal 2001; Østbye et al. 2005). In primary care, provision of all the 
necessary preventive care to the patients could amount to as much as 7.4 hours of advice 
per day to be delivered by the physician (Yarnall et al. 2003). Absence of medication 
adherence from many preventive care efforts is evident in the fact that counseling related 
to adherence can increase the amount of efforts on the part of the physicians (Stevens, 
Sharma, and Kesten 2003).  
Previous studies have shown that physicians fail to follow the NAEPP 
recommendations (Ma and Stafford 2003; Piecoro 2001; Stafford et al. 2003). Many 
potential problems such as large physician case loads, failure to keep up with the latest 
guidelines, lack of incentives for educating patients, fear of potential adverse drug events, 
hassles posed by insurance companies to obtain expensive drugs and devices for the 
patients might be responsible for failure to follow asthma guidelines. Besides these issues, 
many physicians feel trapped in a healthcare system that believes more in the delivery of 
acute care rather than long term care for chronic disease management.  Many practicing 
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physicians also faced the problem of "clinical inertia" characterized by lack of efforts to 
change existent systems or prevalent practice norms (Bodenheimer 2002; Phillips et al. 
2001; Wagner 2001; Ziemer 2005). 
 
2.5 Managed Care 
According to the 106th US Congress, policy actions at multiple levels will be 
required within the social and health systems to effectively deal with issues related to 
asthma.  The Public Health Services Act was amended by the Health Act of 2002 to 
include more preventive and healthcare services associated with asthma.  The 
amendments also allowed for compilation of data and allowed NAEPP to recommend 
national coordination of asthma activities to the Congress (NHLBI, 2005).  In 2002, 
absence of healthcare coverage was witnessed in about 4.3 million or 10.7% children 
(NCHS 2005). At the national level, about 63.9% children have private health insurance 
or any other healthcare coverage as a result of the employer-sponsored group health 
insurance.  Low income children are mostly covered by State Children’s Health 
Insurance Program (SCHIP) and Medicaid.  Medicaid provides coverage to about 1 in 
every 5 children  (about 20%) and SCHIP provides coverage to about 40% of poor 
children respectively (NCHS, 2004). SCHIP mostly provides free healthcare assistance 
without any copayments to children who are ineligible for Medical Assistance (Medicaid), 
private insurance and who fall within the SCHIP income guidelines.  The income 
guidelines are relative to family size and change every year.  Children aged 1-19 years 
below 200 % federal poverty level are eligible for free physician visits, vaccination, 
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surgical procedures, dental procedures, mental health services, preventive healthcare 
services, prescription drugs, hospital visits and stays. 
There are numerous ways to describe managed care. The comprehensive 
definition of managed care includes strategies to control costs and amount of health care 
services rendered to the insured population. It also aims to improve administrative 
efficiency and deliver appropriate care. Managed care involved contractual agreement 
between the patient, the primary care physician and the health plan in order to provide 
medical care to the patients and ensure their proper medical management (Drake 1997; 
Miller and Luft 1994b; Torrens and Williams 1999). 
Along with containing costs, managed care promotes preventive care for 
controlling healthcare expenditures associated with delivery of healthcare services. 
Medicaid managed care in particular, can play an important role for providing a medical 
home, continuous care, improved quality and quantity of care to beneficiaries who 
experience fragmented and uncoordinated care while they were undergoing treatment for 
chronic conditions like asthma (Christakis 2001; Lara et al. 2003; Lieu 2004; Mansour 
2000). 
Managed care was initiated by health maintenance organizations (HMOs) in 
1970s. HMOs can be categorized based on organizational characteristics namely, 1) staff, 
2) group, 3) network, or 4) independent practice association (IPA) models. Some of the 
widely used managed care practices include: 1) risk sharing by both the providers and 
insurers, 2) use of capitation or global ceiling to cover medical expenditures, 3) use of 
primary gatekeepers to constrain costs, 4) drug utilization review, and 5) limiting the 
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number of specialists the patients can choose from (Draper, Hurley, and Short 2004; 
Hurley, Strunk, and White 2004). 
In order to reduce healthcare expenditures, managed care companies emphasize 
preventive care, and reduction of future expenditures. Risk sharing and capitation in case 
of physicians aid in supporting the managed care viewpoint of improving efficiency of 
the private enterprises and free market forces to curtail increasing healthcare expenditures. 
Managed care backlash from providers and patients in 1990s reduced capitated contracts 
due to a flourishing economy and lower healthcare price inflation (Hughes et al. 2004; 
Payne et al. 2000). 
 
2.6 Managed Care Performance 
Miller and Luft wrote many articles from 1993 to 2002 assessing the MC industry 
performance since its inception (Miller and Luft 1993; Miller and Luft 1994a, 1994b; 
Miller and Luft 1997, 2002).  The authors reviewed the impact of MC plans on healthcare 
utilization and medical care, role of quality of care in HMO and FFS indemnity plans and 
the different types of MC designs. These reviews showed that HMO enrollees used less 
and cheaper resources with a focus on preventive services. This evidence was not 
surprising since the basis of HMO was cost containment even though it was achieved at 
the cost of restricted access to care and patient satisfaction. The researchers did not find 
evidence of lower quality of care offered by HMOs in the reviewed literature since 
examine studies had several shortcomings such as use of self-reported data only, shorter 
study duration, small sample size, insufficient data on care rendered to children and data 
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aggregated to the plan level. The researchers also could not control for characteristics 
related to patients, providers, market, and neighborhood while providing medical care 
((Miller and Luft 1993; Miller and Luft 1994a, 1994b; Miller and Luft 1997, 2002). 
 
2.7 Pay for performance measures in managed care (P4P) 
There has been a strong interest in P4P reimbursement programs coupled with a 
hefty dose of optimism among policymakers and health care payers. However, there is 
little published research on the actual impact of P4P. At the heart of the P4P debate is 
whether to reward hospitals and other providers according the achievement of a 
predetermined level of performance or according to improvement in quality measures 
(Rodriguez et al. 2009; Rosenthal 2005, 2006). Both types of P4P programs had their 
critics. Some worry that hospitals that had historically performed above a target level will 
have no incentive to improve if they are able to receive the bonus simply for maintaining 
a status quo (Doran 2008, 2011; Rosenthal 2005, 2006). Others felt that paying for 
improvement may fail to reward those hospitals for whom improvement was likely to be 
more difficult because of their historically high baseline performance (Doran 2008, 2011; 
Rosenthal 2005, 2006).  Within this type of the climate, Rosenthal and colleagues studied 
a P4P experiment conducted within PacifiCare Health Systems. This P4P plan paid a 
bonus for each fixed performance target met. Not surprisingly, they found that providers 
with initially low baseline performance improved the most; however, providers whose 
performance was already above the performance threshold captured the majority of the 
bonus money since payment was based on performance and not improvement (Mullen 
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2010; Rodriguez et al. 2009; Rosenthal 2005, 2006). They concluded that a P4P program 
with a common, fixed performance targets may produce little gain in quality for the 
money spent and will largely reward those providers with a higher baseline performance 
(Mullen 2010; Rodriguez et al. 2009; Rosenthal 2005, 2006). 
P4P is a plan where financial incentives are given to healthcare providers for the 
provision of high quality of patient care. The American Medical Association (AMA) 
defined P4P as “a method of linking pay to a measure of individual, group, or 
organizational performance, based on an appraisal system. These types of bonus 
incentive schemes are based on the idea that work output, determined by some kind of 
measuring system, varies according to effort and that the prospect of increased pay will 
motivate improved performance (AMA, 2005).”  There are three methodologies for P4P 
programs: competitive bonus payment; payment at risk; and quality tiered networks. 
Competitive bonus payments are awarded to top performers in a group of providers and 
bottom performer may or may not receive less compensation. In payment at risk models, 
a percentage of revenue is withheld by the payer until a review of quality scores is 
conducted. Providers who do not meet quality targets lost the percentage at risk. In 
quality-tiered networks, patients are incentivized to select high quality providers by 
offering discounted co-payments. Patients who prefer lower scoring hospitals on quality 
measures must pay higher co-payments (Clinical Advisory Board, 2005). Reimbursement 
is allocated based on providers’ scores on specific quality measures as identified by the 
particular P4P program. 
P4P focuses more on preventive care and where the gains are maximum. As 
examines previously, encouraging medication therapy for controlling asthma in children 
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as a part of P4P could be cost effective in the long run and also be associated with 
reductions in morbidity due to asthma. When one considers the types of performance 
measures for asthma care in P4P, one finds that financial incentives are given to those 
healthcare providers who provide high quality patient care. The four common types of 
performance measures that are used to measure quality of care: process measures, 
outcomes measures, structural measures and satisfaction measures (Johnson and Dinakar 
2010). Among the four measures, P4P consisted of 2 main measures: process measures 
and outcome measures. Process measures consist of processes of care involving taking a 
history or prescribing medications like using inhaled corticosteroids for persistent asthma. 
On the other hand, outcomes measures consist of clinical results reflecting the actual 
health of patients. According to clinicians, process measures can be more controllable 
and attractive compared to outcomes measures. Factors like severity of illness, random 
events and adherence to therapy might affect the control of outcomes measures which 
make it challenging for the providers (Wachter et al. 2008; Werner et al. 2011). 
 
2.8 Theory and Conceptual Framework 
Eisenberg Model of Physician Decision Making 
The Eisenberg model of physician decision making has been widely used to 
characterize physician decision making, physician prescribing and the sociological 
factors that influence physician decision making (Leffler 1981; Tamblyn et al. 2003). In 
this study, the Eisenberg model will be used to study the sociological factors that 
influence physician’s behavior concerning the adoption of financial incentives and 
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prescription of anti-asthma medication. The factors that influence physician behavior are: 
(1) physician characteristics (e.g. age, gender, race, specialty); (2) patient characteristics 
(e.g. age, gender, race, educational level, insurance status, income); (3) physician's 
relationship with the health care system (e.g. practice setting, ownership); and (4) 
physician's relationship with the patient (e.g. patient demand, patient presentation of 
symptoms) (Eisenberg 1979).  Studies have also shown that these 4 factors influence 
physician prescribing (Bradley and Bradley 1991; Gabe 1990).  The influence of these 
four factors on physician decision making is illustrated in Figure 2.1 and described as 
follows: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
               Figure 2.1 Eisenberg model of physician decision making 
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Physician characteristics: Various physician characteristics like their specialty, 
age, gender and personality influence their prescribing decisions. A study showed that 
specialty asthma physicians compared to non specialty physicians were 4.7 times more 
likely to prescribe LM agents and 3 times more likely to prescribe theophylline and 
inhaled steroids in adults respectively (Blanc 2003; Ma 2005). Another study by Janson, 
et al (2004) showed that specialty physicians have a higher likelihood of being aware 
about asthma guidelines, using spirometry to diagnose asthma, using peak flow 
monitoring for monitoring asthma and providing written asthma management plans to 
their asthma patients (Janson and Weiss 2004). 
Patient characteristics: Physician’s decision making concerning the diagnosis 
and treatment of the patient is influenced by patient’s age, gender, educational level, 
insurance status and socioeconomic status. Another study using  data from the 2002- 
2004 National Trauma Data Bank found that patients with lower socioeconomic status 
were being prescribed optimal care compared to their peers with a higher socioeconomic 
status (Mvula et al. 2005). Patient age also plays an important role in their medication 
management.  A study conducted among Medicaid enrollees in Texas showed that 
emergency department visits and the rate of hospitalization is more than twice in 
pediatric patients compared to adults (Smith et al. 2005). There is some evidence of 
patient’s insurance status affecting the quality of care received by them (Eisenberg 1979). 
Physician's relationship with the health care system: According to the 
Eisenberg model, factors like advertising, pharmaceutical sales representatives, 
regulation, physician’s practice setting and physician’s interaction with other healthcare 
professionals can impact physician’s prescribing behavior. A study showed that 
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physicians working for an HMO specifically for a Preferred Provider Organization (PPO) 
were less likely to prescribe LM agents to their patients compared to physicians working 
with other insurers (Blanc 2003). Another study looking at the asthma medication 
prescribing and healthcare utilization among pediatric population enrolled in Managed 
Care Organizations (MCOs) found that about less than 40% of the pediatric population 
was being prescribed controller medications compared to reliever medications (Donahue 
et al. 2000). 
Physician's relationship with the patient: Physician patient interaction also 
influences decision making and physician prescribing. Patient’s demands and symptom 
description might be different than physician’s decision.  A systematic review by Stewart 
in 1995 showed that a majority of the studies dated from 1983 to 1993 showed that 
effective patient physician interaction influenced physician’s decision making which in 
turn led to better health outcomes (Stewart 1995).  According to Eisenberg’s model, 
patient physician interaction is classified into 3 categories: a) “activity passivity” where 
decisions are made primarily by physician and patients follow the decisions blindly, b) 
"guidance-cooperation" where the physician guides the patient and the patient accepts the 
physician’s advice and c) "mutual-participation" where both the   
patient and the physician participate and come to a mutual agreement (Eisenberg 1979). 
 Eisenberg’s model includes different factors that influence physician decision 
making for prescribing anti-asthma medications. This model is also suitable for selecting 
independent variables for the study.  Hence this model proves as a favorable choice for 
this study. 
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Aday-Anderson Model of Health Service Utilization 
This conceptual idea resonates with a commonly used model proposed by 
Donabedian which posits that a complex set of underlying factors interact to impact 
health-related outcomes (Donabedian, 1974).  In this study, applying this framework 
demonstrates that various factors (i.e., the structure) exert influence on the likelihood of 
anti-asthmatic medications’ adherence (i.e., the process), which in turn impacts the risk of 
both all cause and asthma-related events and complications and associated resource use 
(i.e., the outcome).  
The “structure” element of this conceptual model can further be subdivided into 
predisposing, enabling, and need-related factors. The predisposing factors include those 
variables that exist prior to the disease and which describe the propensity of individuals 
to use services. The enabling factors are the variables that indicate the resources that are 
available to the individuals so that they can make use of health services. The need based 
factors indicate the illness level or need for care received by the individual or the 
physician. In this study, predisposing factors will be included age, race and gender; 
enabling factors will be included health care system, treatment characteristics, and 
physician characteristics; and need factors will include asthma severity and asthma drug 
ratio. The asthma drug ratio is the ratio of the controller medication to total asthma 
medication. A higher asthma drug ratio is associated with less asthma related ED visits, 
better quality of care and better patient centered asthma outcomes (Schatz 2006).  The 
“process” element of this framework is a measure of medication adherence. Finally, the 
“outcome” element will be included event and resource use parameters such as existence 
of likelihood of events, and healthcare utilization, all cause and asthma-related. 
  36
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 Figure 2.2 Aday-Anderson healthcare utilization model & SPO model  
 
 
 
Proposed Conceptual Framework 
 To capture the physician prescribing behavior of anti-asthmatic medications and 
patient treatment choices, a proposed model of Eisenberg model of physician decision 
making as well as Anderson healthcare utilization model was proposed as a conceptual 
framework for this study which is shown as Figure 2.3 
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Figure 2.3 Proposed Conceptual model of this study 
 
Note: 
 
 The solid lines represents the associations this study attempted to address and the 
dashed lines imply an influencing effect that could not be directly measurable but 
had a strong theoretical association 
 
The current study combined the tenets from the Anderson model and Eisenberg 
model.  The concept of physician decision making about anti-asthma medication is based 
on the Eisenberg model and it is influenced by four sociological factors listed as follows: 
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patient characteristics, physician characteristics, health care system, and physician 
relationship with patients.  The concept of children’s medication adherence is based on 
the Anderson model and is considered to be influenced by predisposing, enabling, and 
need factors. The solid lines show associations that the proposed study addresses whereas 
the dashes show associations that indicate an influence rather than a direct impact on the 
outcome. 
The proposed model provides a comprehensive process with regards to 
the influence of use of anti-asthmatic medications on patient medication 
adherence and health outcomes.  In the later sections, the relationships 
between appropriate medication choice, anti-asthmatic medication 
adherence and associated health outcomes will be analyzed using various 
statistical approaches.  The results obtained from the same will provide a 
better insight about the associations of the aforementioned variables.
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CHAPTER 3 
RESEARCH METHODS 
 
In this section, the statistical approaches that are implemented to investigate each 
objective of this study are described. All data management and analyses were performed 
using the SPSS® (version 15) and STATA® (version 10) statistical software packages. 
 
3.1 Study Design 
This study was a retrospective cross-sectional study which used the National 
Ambulatory Medical Care Survey (NAMCS) and MarketScan® Claims datasets. The first 
manuscript of this study aimed to disentangle physician’s prescribing behavior for anti-
asthmatic medications in asthmatic children, using logistic regression as well as the 
multinomial logistic regression model. The second manuscript of this study examined the 
impact of Medicaid payment system on healthcare utilization and medication adherence 
in asthmatic children enrollees, using quantile regression, logistic regression, and count 
regression models. The third manuscript of this study is compared health outcomes for 
Medicaid and privately insured children in a commercial insurance plan, using quantile 
regression, logistic regression, and count regression models. The NAMCS and 
MarketScan® claims datasets, study sample eligibility criteria, measures and the 
econometric models are introduced in the following sections. 
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3.2 Data Sources 
National Ambulatory Medical Care Survey (NAMCS) 
 
The first manuscript used the National Ambulatory Medical Care Survey 
(NAMCS) to study the impact of P4P based financial incentives on medication 
prescribing behavior of anti-asthmatic medications. The NAMCS is a national probability 
sample survey conducted by the Division of Health Care Statistics of the National Center 
for Health Statistics (NCHS) and the Centers for Disease Control and Prevention (CDC). 
The data for NAMCS has been archived on an annual basis for the years 1973-1981, for 
1985 and from 1989-present. The sampling frame consists of records of physician names 
preserved by the American Medical Association and the American Osteopathic 
Association comprises the NAMCS data. The study involves visits to non-federally 
employed office-based physicians providing direct patient care and belonging to all 
specialties except anesthesiology, radiology, and pathology. 
Data for the NAMCS is collected using a three-stage probability sampling design. 
The initial or the first probability sample is taken from primary sampling units (PSUs) 
(n=112 PSUs). These PSUs consists information on counties, county groups, towns, 
townships and county equivalents.  The second stage probability sample involves data 
based on physicians’ working within each of the PSUs whose data is archived in the 
master files. The third stage probability sample includes a random sampling of visits to 
physician offices.  The reporting period for each physician lasts about a week whereby 
either the physician or any office staff of physician collects information about patient’s 
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socio demographics, specialty of physician, reasons for physician visit, method of 
payment for the physician visit, patient symptoms, diagnosis of patient symptoms, 
complaints made by the patients, drugs prescribed by the physicians, first time or regular 
visit, preventive and therapeutic care provided of recommended.  The encounter between 
physician and patient or outpatient visit comprises the basic sampling unit in the NAMCS 
database. In order to calculate national estimates, each data record is inflated using an 
inflation factor known as the patient visit weight. This weight helps researchers to 
determine the overall office visits that took place in US. There might be some sampling 
variability observed. However, an estimate is deemed reliable by NCHS standards if the 
relative sampling error is less than 30% of the estimate. 
 
MarketScan® Medicaid/Employer sponsored Claims 
The second and third manuscripts of this study (Chapter 5 & 6) use the 
MarketScan® Medicaid/employer-sponsored claims dataset licensed from Thomson-
Reuters. It consists of data from 8 different states of varying size and dispersed all across 
the U.S (MarketScan® research database, 2008). The states are de-identified. However, 
the data consist of at least one state from each U.S. region. The database consists of 
medical (outpatient and inpatient services), drug, and long-term care claims and 
eligibility records for enrollees from these states. The prescription drug coverage was 
provided by all the states. The data are available from 2003 to 2007 representing around 
7.4 million individuals in the United States (MarketScan® research database, 2008). For 
the purposes of this study, the Medicaid/Commercial database are updated and queried 
from January 1, 2005 to December 31, 2007. The database is HIPPA compliant and 
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features encrypted member and service provider identification numbers. The data from 
these states will provide a fairly large sample of the Medicaid/employer-sponsored 
enrollees in the U.S. The dataset also provides additional information on variables such 
as race/ethnicity, Medicare eligibility and Medicaid eligibility / federal aid category. 
 
3.3 Study Population 
For the first manuscript of this study, the study sample of the first manuscript 
were children with a primary diagnosis of asthma (ICD-9 code 493.XX) and the 
mentioned of the word ‘asthma’ in the office visit. There were age restrictions (less than 
18 years old) for the target population but patients with co-morbid conditions that could 
confound study findings were excluded from the analysis.  
For the remaining manuscripts of this study, the study population comprised of 
children aged 0 to 18 years of age. The patients with a diagnosis of asthma and a 
prescription of a new asthma medication (Inhaled Bronchodilator, Anti-Inflammatory, 
Systematic Bronchodilator, Systematic Corticosteroid and/or Leukotriene Modifiers) 
during the study time period were included. Subjects with a primary or secondary 
diagnosis of asthma were identified using the International Classification of Diseases 
Code 9th Revision (ICD-9: 493.XX) from the inpatient claims during the study test 
period. Only subjects who maintained continuous eligibility for 1 year period between 
January 1, 2005 and December 31, 2005 were included in the study. The date for the first 
prescription claim for anti-asthmatic medication use was designated as an index date, 
where the medication was identified using relevant National Drug Codes (NDC) recorded 
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in the claim records. Drug manufacturers provide the Food and Drug Administration 
(FDA) information about all the drugs manufactured, prepared, propagated, compounded, 
or processed by them which are to be distributed for commercial purposes. Each drug is 
identified using a specific 10 digit, three-segment number which is the National Drug 
Code (NDC). The NDC is a universal measure of identifying labeler, product, and trade 
package size of the drugs available for human consumption.  The labeler code of the drug 
is the first segment of the NDC. It assigned by the FDA, indicates the firm that 
manufactures or repackages or re-labels or distributes (under its own name) the drug. The 
product code is the second segment of the NDC. It is assigned by the firm and it identifies 
the strength, dosage form, and formulation of the drug. The package code is the third 
segment of NDC. It is assigned by the firm and it identifies the package sizes and types. 
The annual consumption of the anti-asthmatic medications was defined as the claims 
received for each specific prescription identified using the NDC. (FDA 2012) The study 
required all patients to have continuous health plan enrollment for at least 1 year prior to 
and following their index date by insuring that each patient’s index date presents a 
reasonable marker for treatment initiation as well as making sure that any observed lack 
of health care events is due to a lack of medical activity and not due to cessation of 
insurance. The identification period ranged from January 1, 2006 to December 31, 2007. 
During this time period, any patients who had an asthma diagnosis and who were 
prescribed an anti-asthmatic medication were included. 
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3.4 Covariates and Measures 
 
Categories of Anti-asthmatic medications 
 The primary dependent variable for the first manuscript were the different asthma 
drug classes classified under the broad categories of controller versus reliever 
medications used in the management of asthma. These drugs are classified on the basis of 
their role in the management of asthma and fall into the general categories listed in Table 
3.1. Based on the nature of the NAMCS dataset, it was difficult to ascertain whether these 
medications are in the CM or the RM group. Based on clinical knowledge, we decided to 
place this category in the RM group.  
 
Table 3.1 Drug Classes in the Pharmacotherapy of Asthma 
Controller Medication (CM) Reliever Medication (RM) 
Inhaled Corticosteroids (ICS) Short Acting Beta Agonist 
bronchodilators (SABA) 
Oral Corticosteroids (OC) Oral Corticosteroids (OC)* 
Long Acting Beta Agonist 
inhalers (LABA) 
Oral Short Acting Beta 
Agonists (OSABA) 
Leukotriene Modifiers 
(LM) 
Oral Short Acting 
Xanthines (OSAX) 
Inhaled Cromones (CI) Anti-Cholinergic 
Bronchodilators (ACB) 
Oral Long Acting beta Agonists (OLABA) Combination of SABA and 
ACB (BAACB) 
Oral Long Acting Xanthines (OLAX)  
Combination of LABA and ICS (LABIC)  
Notes: *The issue of the oral corticosteroid (OC) class in the analysis was complicated. 
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Measurement for the Manuscript 1 
 This study used the Eisenberg physician decision making model as the 
structural framework. According to this model, the physician decision making is 
influenced by four social factors: (1) physician characteristics; (2) patients characteristics; 
(3) physician as a part of the health care system; and (4) physician’s relationship with the 
patient. All the above factors are described in details in the previous sections.  
               The dependent variables of the study were physician prescribing of anti 
asthmatic medication and the type of anti-asthmatic medication prescribed. The 
dependent variables were taken from the NAMCS prescription data and classified as per 
the prescribed medications listed in table 6. Manuscript 1 analyzed the impact of financial 
incentives on physician’s medication prescribing behavior in outpatient asthmatic 
children. The socio demographic characteristics of the children included age, gender, 
race/ethnicity, and payment structure. The race/ethnicity was classified as Hispanic and 
non Hispanic. The payment structure was classified by method of payment (capitation/no 
capitation) and by percentage of financial incentives from P4P. All the measures of the in 
dependent variables are summarized in Table 3.2. 
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Table 3.2 Study covariates for Manuscript 1 
1. Physician Characteristics 
    Provider: Pediatrician Non-Pediatrician 
3. Physician’s Relationship with the Health  
    Care System 
    Ownership status: Owner of solo practice 
      Owner of non-solo practice, Non-owner 
    Geographic region of practice: 
      Northeast, Midwest, South, West 
    Metropolitan area: yes   
2. Patient Characteristics 
    Gender: male 
    Age 
    Race/ethnicity: White, Black, Hispanic,  
       Other 
    Capitated payment: yes 
    Financial incentives: % of bonus 
 
4. Physician’s Relationship with the patient 
    Patient seen before: yes 
    Asthma is the primary diagnosis listed for  
    the visit: yes 
 
In the first manuscript of this study, the patient characteristics included age, 
gender, race/ethnicity, and payment structure. A patient’s race/ethnicity was categorized 
as Hispanic and non-Hispanic (Whites, Blacks and others), Payment structure included 
method of payment (capitated or not) and the percentage of bonus incentives. One of the 
limitations of NAMCS is that it provides limited information about physician 
characteristics. Among physician characteristics, it includes the physician specialty 
categorized as pediatricians and non-pediatricians. Physician’s relation with the 
healthcare system was characterized by his/her geographic location of practice (Northeast, 
Midwest, South and West, metropolitan and non metropolitan areas) and physician’s 
ownership of practice (solo, non solo and non owner). Patient physician relationship was 
categorized by first or routine visit and if asthma was the primary cause of physician visit. 
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Measurement for the Manuscript 2 and 3 
The operational definitions and measurements of the variables utilized in 
manuscript 2 and 3 are discussed in this section. The dependent variables for this study 
were medication adherence, hospitalizations, emergency room (ER) visits and asthma-
related healthcare costs. The independent variables tested in this study were payment 
mechanisms (capitated vs. fee for service) and types of patient claims (Medicaid vs. 
Commercial plans). Other independent covariates included age, gender, access to 
specialty care, and disease severity. The operational definition of each variable is 
described in the following sections: 
 
Medication adherence 
Medication adherence was used to measure medication usage by patients. 
Medication adherence is basically the act of conforming to the physician’s 
recommendations about the timing, dosage, and frequency of medication intake.  The 
International Society of Pharmacoeconomics and Outcomes research defines medication 
adherence as the extent to which a patient complies with the intended dosing regimen 
(Hess 2006). The unit of measure for medication adherence is administered doses per 
defined period of time, reported as a proportion (%) of prescribed doses (D) taken at the 
prescribed time interval (T) as measured by the period of time.   
Medication adherence can be measured directly and indirectly by utilizing 
biological markers, blood and urine assays, patient interviews, pill counts, prescription 
refills, and electronic monitoring (Claxton, Cramer, and Pierce 2001; Hess 2006). Since 
the study used an insurance claims database, prescription refill patterns were used to 
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capture medication adherence. The information thus obtained recorded the frequency and 
timeliness of refills of prescribed medication and eliminates any Hawthorne effect. Also 
pharmacy records had predictive validity as measures of cumulative exposure and gaps in 
medication supply (Steiner 1998). On the other hand the method also had some 
limitations like presence of data on unusual refill patterns, multiple conflicting drugs and 
inability to capture all data about patients visiting multiple pharmacies. Also utilization of 
pharmacy records assumed that “a prescription filled is a prescription taken” 
(Balkrishnan 2005). The data cannot measure actual consumption but only estimates 
about actual medication consumption (Hess 2006). 
 
Working Definition of Medication adherence 
Medication adherence in this study indicated patient’s intake of anti-asthmatic 
prescription medication. Data from the pharmacy claims database can be used to measure 
medication adherence by several ways. Medication possession ratio (MPR) is one such 
measure used to calculate medication adherence. For the purposes of this study, MPR 
was calculated as the days of anti-asthmatic medication supply dispensed divided by the 
number of days in the observation period (#365) minus the number of days in the hospital 
(Camargo 2007; Hess 2006; Sokol et al. 2005). Previous studies have shown that 
medication adherence measurement for the entire study period which is 365 days in this 
study, when used as a denominator, predicts hospitalization and healthcare costs in a 
more appropriate manner compared to adherence measures considering the period 
between the first and last refill (Camargo 2007; Mattke et al. 2010). Medication 
adherence measures like MPR, proportion of days covered (PDC), Continuous 
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Medication Gap (CMG) and Continuous Multiple interval of Oversupply (CMIOS), 
Medication Refill Adherence (MRA) use the entire study period as a denominator. Also 
measures like Refill compliance rate (RCR), compliance rate (CR), and modified 
medication possession ratio (MPRm) which measure the period between the first and last 
refill lack a consistent denominator value while calculating adherence (Hess 2006). The 
above measures fail to account for early medication discontinuation, thereby 
overestimating adherence for patients stopping their medication intake when they should 
be taking it. Therefore, MPR for this study is defined as  
MPR= # of days supply of anti-asthmatic medication in the post-index period / # of days 
in the study period (365 days). 
  
 # of days supply of anti-asthmatic medication in the post-index period indicates the 
supply of the dispensed anti-asthmatic medications will last. The Marketscan Medicaid 
database had claims for a 30 days supply of anti-asthmatic medications.  The days supply 
was calculated by dividing the total amount of dispensed anti-asthmatic medications by 
the maximum amount of anti-asthmatic medications used in one day. The observation 
period in this study included the post-index period or 12 month follow up period which 
was consistent for each patient. The number of hospital days was subtracted from the 
denominator because any drug taken during this period was given to the patient by the 
hospital and was not possible to capture in the pharmacy records. The information on 
each filled prescription included of dispensing, quantity dispensed, and days supply of 
medication. 
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Healthcare Service Utilization 
Patients were followed during pre-index and post-index period (i.e. 12 month 
before and 12 months after the index date) to assess their healthcare utilization in terms 
of hospitalizations, ER visits, outpatient visits. The variables hospitalizations, ER visits 
and outpatient visits are used as a proxy for health care service utilization. To identify 
hospitalization event in patients, their admission and discharge dates recorded in inpatient 
service files are used. CPT codes as well as service codes were taken from the inpatient 
and outpatient services files for identifying events of ER visit and outpatient visits. 
 
Sociodemographic Vaiables 
The following sociodemographic variables were taken from the data: gender, birth 
year and race/ethnicity. Gender of the patients was categorized into males and females. 
Birth year of the patients was used to calculate their age. Race or ethnicity of patients was 
classified as whites, blacks, Hispanics and others. The Medicaid dataset also had 
information about the health plan (capitated or fee for service) patients were enrolled in. 
 
Medication/Therapy related variables 
The National Drug Code (NDC) code was used for identifying anti asthmatic 
prescription medications.  Besides anti asthmatic prescription medications, the total 
consumption of different prescription medications was also noted. The specialty of the 
physicians whom the patients visited (e.g. pediatrician, internal medicine, family 
practitioner/general practitioner) was also identified. 
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Proxy for Asthma Severity 
Based on the established relation between disease severity and intensity of 
treatment, severity of a condition in the current period was inferred by a risk of an 
exacerbation in a future. Some of the independent predictors widely used in the literature 
for ascertaining future asthma-related emergency hospital utilization (EHU) are 
hospitalizations, use of emergency department and use of oral corticosteroids (Roth 2004; 
Schatz 2004). Severity of asthma in the current period was assessed by determining high 
risk of EHU. Risk stratification schemes were developed using pharmacy claims or 
facility claims or a combination of both.  Combination of pharmacy and facility claims 
are more successful in stratifying risk compared to using pharmacy or facility claims 
single-handedly (Roth 2004; Schatz 2004). 
 A popular type of risk stratification scheme used is a simple three-level risk 
stratification which ranks risk of future Emergency Hospital Utilization  (EHU) based on a 
point system applied to a period portraying current utilization. Points are assigned to 
different indicators of future asthma related EHU. Asthma hospitalizations or ED 
encounters in the 12-month base period are assigned 2 points, 15 or more beta-agonist 
canisters in the base period are assigned 1 point and 1 or more filled prescriptions for oral 
corticosteroids are assigned 1 point. Members are differentiated on the basis of 
assignment of points. Members with 2 or more points, 1 point and 0 point are classified 
as high risk, medium risk and low risk groups respectively (Schatz 2004). This has been 
summarized in the following Table 3.3. 
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Table 3.3 Three-Level Risk Stratification of Asthma Severity 
 
Event per 12-
month base 
period 
Potential Point 
Assignment 
Low Risk 
0 Points 
Medium Risk 
1 Points 
High Risk 
2 or more 
Points 
A. ED visits 
asthma 
encounter 
2 0 0 2 
B.  IP visits 
asthma 
encounter 
2 0 0 2 
C. 15 or more 
beta-agonist 
canisters 
dispensed 
1 0 1 1 
D. Any oral 
corticosteroid 
prescriptions 
dispensed 
1 0 1 1 
Required events 
for risk level 
 No listed 
events 
Either C or D Either A or B 
and/or C and D
 
 Therefore, the measurement of asthma severity is the probability of an asthmatic 
member having a risk score (severity proxy) of 0,1, or 2. 
 
Type of Health Plans (FFS vs. Capitation) 
The Medstat MarketScan® Medicaid database provided patient level indicator 
variable for the type of health plan enrolled for by each patient. Medicaid has classified 
plans into 2 groups (MarketScan®  Medicaid database user guide, 2005):  
1. Capitation: it represented capitated managed care plan where MCOs receive a fixed 
amount of payment per enrollee per month. All or some services offered by MCOs are 
paid on a capitated basis.  
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2. Fee-for-service (FFS): it indicated health plans that pay providers or physicians on the 
basis of services rendered. There is no incentive for the patient to use a particular list of 
providers. Coverage is handled by only one policy, with a deductible and coinsurance. 
The patient level variable is coded as 1 for capitation and 0 for FFS health plan. 
 
Table 3.4 Analytical Framework and study covariates for manuscript 2 and 3 
Target population: Children aged 0 to 18 years with a diagnosis of asthma receiving  
                                 care in a Medicaid Setting and/or Commercial plan 
Outcomes: Medication Possession Rate, and Healthcare services utilization (ER, IP &  
                    OP) 
Regressor of interest: Health plans (FFS vs. Capitated) – for the manuscript #2 
                                      Health plans (Medicaid vs. Commercial) – for the manuscript #3 
Covariates: 
Patient Characteristics: Patient’s age, gender, and race/ethnicity (Predisposing   
                                                                                                            factors) 
Patient’s Medical Conditions: Asthma severity                              (Need factors) 
Physician Characteristics: Specialty                                              (Enabling factors)  
Asthma drug ratio: A controller to total asthma medication ratio of 0.5 or more 
  
3.5 Statistical Analysis Plans 
Manuscript # 1: To assess the influence of P4P financial incentives on anti-asthmatic 
medication prescribing behavior using the National Ambulatory Medical Care Survey 
(NAMCS) for the year 2007. National estimates on asthma-related ambulatory were 
estimated using ‘patient visit weight’ provided in the NAMCS dataset. For the first 
manuscript, logistic models will be built. The followings are descriptions of the models 
for the first study: 
Pr [Y [Only Controller Medication prescribed] = 0 or 1] 
= f [ß0 + ß1 (patient factors) + ß2 (physician factors) 
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+ ß3 (physician - health care system interaction factors) 
+ ß4 (physician - patient interaction factors)] + e 
where Y = 0 if no controller medication is prescribed, Y = 1 if controller medication is 
prescribed; f(•) is the cumulative density function (CDF) of logistic distribution and e is 
the error term. 
Pr [Y [Controller & Reliever Medications (both) prescribed] = 0 or 1] 
= f [ß0 + ß1 (patient factors) + ß2 (physician factors) 
+ ß3 (physician - health care system interaction factors) 
+ ß4 (physician - patient interaction factors)] + e 
where Y = 0 if no medication is prescribed, Y = 1 if both medications are prescribed; f(•) 
is the cumulative density function (CDF) of logistic distribution and e is the error term. 
Pr [Y [Only Reliever Medication prescribed] = 0 or 1] 
= f [ß0 + ß1 (patient factors) + ß2 (physician factors) 
+ ß3 (physician - health care system interaction factors) 
+ ß4 (physician - patient interaction factors)] + e 
where Y = 0 if no reliever medication is prescribed, Y = 1 if reliever medication 
prescribed; f(•) is the cumulative density function (CDF) of logistic distribution and e is 
the error term. 
Manuscript # 2: To examine the impact on health care utilization and medication 
adherence in asthmatic children Medicaid enrollees using the MarketScan® Medicaid 
Claims for the year 2007.  The following is the description of the models for the second 
study: 
MPR (anti-asthmatic medication adherence-quantile regression) 
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= ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (Capitated vs. FFS) + e 
Where MPR stands for the medication possession ratio to measure anti-asthmatic 
medication adherence and e is the error term. 
Pr [Y [health care utilization] = 0 or 1] 
= f [ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (MPR) + ß6 (Capitated vs. FFS)] + e 
where Y = 1 if some specific health care is utilized and Y = 0 if not; f(•) is the cumulative 
density function (CDF) of logistic distribution and e is the error term. 
Asthma-related healthcare utilization (a count variable, the number of visits) 
= ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (MPR) + ß6 (capitated vs. FFS) + e 
Where count model consists of poisson regression and negative binomial regression, e is 
the error term. 
Manuscript # 3: To examine the health outcomes for Medicaid and privately insured 
children in a commercial insurance plan for the year 2007.  Before the main outcomes were 
examined, differences across the two populations studied were tested using a Chow test (Lo, 
1985). The Chow test examines whether a regression function is different for one group 
(Medicaid) versus another (Privately Insured). It can be thought of as simply testing for the joint 
significance of the dummy and its interactions with all other covariates, to determine if the two 
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datasets can be combined for hypothesis testing purposes. Therefore, we estimated the model 
with all the interactions and without the interactions and form an F statistic to test if variables are 
jointly 0.  In our case, the Chow test is used to examine if data for the two groups can be ‘pooled.’ 
After pooling data with Medicaid and private insurance, we computed the proper F statistic 
without running the unrestricted model with interactions with all the k continuous variables.  
MPR (anti-asthmatic medication adherence-quantile regression) 
= ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (Medicaid vs. Commercial) + e 
Where MPR stands for the medication possession ratio to measure anti-asthmatic 
medication adherence, and e is the error term. 
Pr [Y [health care utilization] = 0 or 1] 
= f [ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (MPR) + ß6 (Medicaid vs. Commercial)] + e 
where Y = 1 if some specific health care is utilized and Y = 0 if not; f(•) is the cumulative 
density function (CDF) of logistic distribution and e is the error term. 
Asthma-related healthcare utilization (a count variable, the number of visits) 
= ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (MPR) + ß6 (Medicaid vs. Commercial) + e 
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Where count model consists of poisson regression and negative binomial regression, e is 
the error term. Additionally in all cases, a logistic regression was also used to determine 
predictors of the likelihood of a type of health care service utilization.  
 
 
3.6 Regression Diagnostics 
  An OLS regression model has to meet several statistical assumptions like 
existence, linearity, independence, homoscedasticity, and normality so that the 
experimenter can obtain robust estimates. Existence indicates the dependent variable Y 
which is random with a finite mean and has it's variance in the population. The mean and 
the variance of Y depends on the value of the independent variable, X. Linearity means 
that the mean value of Y is a straight-line function of X. The study population meets the 
statistical assumption for existence and linearity. For example, the MPR is a linear 
function of the key independent variables and other covariates. In this study, the other 
statistical assumptions like independence, homoscedasticity and normality were met by 
implementing several regression diagnoses. This ensured that the OLS regression models 
performed in this study met the statistical assumptions. The statistical tests performed for 
fulfilling individual statistical assumptions are described in detail in the following 
sections. 
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Autocorrelation 
  Independence assumes that the value of each dependent variable is not correlated 
with the other independent variables. It means that each Y is independent of the other Ys 
in the study. Most of the cross sectional studies meet the statistical assumption of 
independence. In some cases, this assumption can be violated. When the values of 
multiple observations recorded over a period of time in the same subject are correlated, 
the phenomenon is called autocorrelation.  
Autocorrelation might be common especially when studying medication 
adherence behavior in patients with chronic diseases. It is difficult to obtain robust 
estimates in the OLS regression model when autocorrelation exists. Autocorrelation can 
be detected in the regression model using the Durbin-Watson statistic test. The null 
hypothesis of the Durbin-Watson test is absence of autocorrelation over time. The value 
of the Durbin-Watson statistic test should be between 0 and 4. If the value of the Durbin-
Watson statistic is 2, it means there is no autocorrelation exists between Y values over 
time. If the Durbin-Watson statistic is close to 0, then a positive autocorrelation exists. If 
the statistic is close to 4, a negative autocorrelation exists. Autocorrelation can be 
corrected using lagged variables in the OLS regression or GLS (general least squares) 
regression. 
 
Heteroskedasticity 
 Heteroskedasticity means that the variance of Y (the dependent variable) is the 
same for any given X (the independent variable). It is a violation of the assumption with a 
constant variance. The presence of outliers and skewness can result in heteroskedasticity. 
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It can also result in a narrow range of the confidence interval which in turn can result in 
easy rejection of the null hypotheses in spite of the fact that the point estimates (OLS 
coefficients) are unbiased.  
 The statistical test that can detect the presence of heteroskedasticity in the OLS 
regression model is the Busch -Pagan-Godfrey test. This test examines the dependence of 
the estimated variance of the residuals in an OLS regression model on the values of the 
independent variables. If heteroskedasticity exists in the OLS regression model, there is a 
possibility that there is correlation between the estimated variance of the residuals and the 
independent variables. Heteroskedasticity can be rectified with GLS regression which 
attaches equal weights to each observation. 
 
Normality 
 Normality indicates normal distribution given any fixed value of X and Y. In 
order to obtain robust point estimates and confidence intervals, it is important to ensure 
that an OLS regression model meets the normality assumptions. This also makes the OLS 
regression model accurate and reliable. Normality can be detected using the Shapiro-Wilk 
test and a plot histogram of residuals. To make the model normal, a log-transformation of 
the Y (dependent)-value can be performed sometimes. The log transformation also makes 
the model homoskedastic. 
 
Multicollinearity 
 Multicollinearity in the model can be detected by using the variance Inflation 
Factor (VIF). VIF is an index that measures the magnitude of the change in variance of 
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an estimated coefficient that might be a consequence of multicollinearity. The VIF value 
is directly proportional the magnitude of multicollinearity in the model. If the VIF value 
is more than 10, it indicates that there is severe mutlicollinearity in the OLS regression 
model. The re-specification of the OLS regression model can correct mutlicollinearity. 
This study had no multicollinearity issues. 
 
 
3.7 Conducting Overall Conclusions 
With reference to the previous chapters and sections, this dissertation discusses 3 
different but interlinked objectives. Statistical analyses have been conducted differently 
for each of the objectives and have been reported in three different chapters. Overall, all 
the three chapters try to study the impact of use of anti-asthmatic medications from 
patient and physician perspective, on patient health outcomes. The outcome of this 
dissertation was drawn from the proposed model described in Figure 2.3. 
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CHAPTER 4 
DISSERTATION MANUSCRIPT #1: ASSOCIATIONS BETWEEN PHYSICIAN 
FINANCIAL INCENTIVES AND PRESCRIBING OF ANTIASTHMATIC 
MEDICATIONS IN CHILDREN IN US OUPTIENT SETTINGS 
 
     ABSTRACT 
This study examined how sociological factors including financial incentives influenced 
whether asthmatic children received a controller medication, a reliever medication or 
both. The 2007 National Ambulatory Medical Care Survey (NAMCS) was used for this 
analysis. A logistic regression was applied to capture the physician’s decision making 
and to analyze anti-asthmatic medication choice. Children with asthma seeing a pediatrician 
were approximately 69% more likely than children seeing a family doctor to receive a controller 
medication than reliever medication (p<0.01). Children with asthma enrolled in a capitated plan 
were 23% more likely to receive controller medications than reliever medications (p<0.01). 
Children with asthma of Hispanic ethnicity were 28% less likely to receive controller medication 
compared to Non-Hispanic White (p<0.05) children. Compared with physicians who received 
lower financial incentives, physicians who received medium (39%, p<0.05) or higher (42%, 
p<0.01) financial incentives from payers were more likely to prescribe controller medication than 
reliever medication for children with asthma. An important finding of this study is that physicians 
who had medium or higher financial incentives from payers were about 40 % more likely to 
prescribe a controller medication in children with asthma. Findings suggest that physician 
incentives and capitated plans are associated with increase in physicians prescribing controller 
medications or preventive care in children with asthma.  
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Introduction 
Asthma is a chronic respiratory disease characterized by episodes or attacks of 
inflammation and narrowing of small airways in respiratory system. (Akinbami et al. 
2009; Chang et al. 2011). Some of the most established measures of prevalence of asthma 
are the Center for Diseases Control’s (CDC) Behavioral Risk Factor Surveillance Survey 
(BRFSS) and the National Health Interview Survey (NHIS) (Crosson et al. 2009). These 
surveys had the usual limitations associated with self-reported data like non-response bias, 
and low precision for state and sub-state estimates associated with surveys that used 
multistage sample selection with the goal of developing national estimates. Given these 
limitations, estimates of the lifetime prevalence of asthma among adults had ranged from 
10-12% over the past 6 years while current asthma for adults is generally reported at 
approximately 7-8% (Mannino 2002). National estimates suggested that lifetime asthma 
prevalence for children less than 18 was approximately 12.5% with age specific 
prevalence of 7.5, 14, and 14.7 percent for children aged 0-4, 5-11, and 12-17 
respectively (Mosen 2005). Therapeutic asthma drugs were summarized into four major 
types: 1) Bronchodilators, 2) Corticosteroids, 3) immunotherapy, and 4) anti-IgE 
antibodies. Among all the therapeutic asthma drugs, corticosteroids were the most 
effective for controlling asthma symptoms and serving as evidence of preventive asthma 
care (Cisternas et al. 2003; Dougherty 2005; Finkelstein 2002). 
Pay for performance (P4P) is a physician incentive mechanism where financial 
incentives are given to healthcare providers for the provision of high quality of patient 
care. The American Medical Association (AMA) defines P4P as “a method of linking pay 
to a measure of individual, group, or organizational performance, based on an appraisal 
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system. These types of bonus incentive schemes are based on the idea that work output, 
determined by some kind of measuring system, varies according to effort and that the 
prospect of increased pay will motivate improve performance (Rodriguez et al. 2009).” 
There is strong interest in pay for performance (P4P) reimbursement programs coupled 
with a hefty dose of optimism among policymakers and health care payers. However, 
there is little published research on the actual impact of P4P. At the heart of the P4P 
debate is whether to reward health care providers according the achievement of a 
predetermined level of performance or according to improvement in quality measures 
(Doran 2011; Rosenthal 2005, 2006; Sempowski 2004). Both types of P4P programs had 
their critics. Some worry that healthcare providers that had historically performed above 
a target level will have no incentive to improve if they were able to receive the bonus 
simply for maintaining a status quo (Conrad 2004; Doran 2008; Ho 2010; Rosenthal 2005, 
2006). Others felt that paying for improvement may fail to reward those providers for 
whom improvement was likely to be more difficult because of their historically high 
baseline performance (Hartert et al. 2010; Ho 2010; Jansson et al. 2007; Johnson and 
Dinakar 2010; Rosenthal 2005, 2006).  Another set of studies concluded that a P4P 
program with a common, fixed performance target may produce little gain in quality for 
the money spent and will largely reward those providers with a higher baseline 
performance (Ho 2010; Mullen 2010; Rosenthal 2006; Stanley J 2010).   
However no published study exists which has examined the impact of physician 
financial incentives on prescribing controller medications in children with asthma.  This 
could be an important factor in examining whether such financial incentives incentivize 
physicians to promote more preventive medicine. This study used the National 
  64
Ambulatory Medical Care Survey (NAMCS) along with Eisenberg model of physician 
prescribing as the conceptual framework to examine the impact of the financial incentives 
on physician’s medication prescribing behavior in asthmatic children of outpatient care in 
the U.S. 
 
Materials and Methods 
 The NAMCS is a national probability sample survey conducted by the Division of 
Health Care Statistics of the National Center for Health Statistics (NCHS) and the 
Centers for Disease Control and Prevention (CDC). The sampling frame consists of 
records of physician names preserved by the American Medical Association and the 
American Osteopathic Association comprises the NAMCS data. The study involves visits 
to non-federally employed office-based physicians providing direct patient care and 
belonging to all specialties except anesthesiology, radiology, and pathology 
Data in NAMCS was collecting using a three-stage probability sampling design. 
The initial or the first probability sample is taken from primary sampling units (PSUs) 
(n=112 PSUs). These PSUs consists information on counties, county groups, towns, 
townships and county equivalents.  The second stage probability sample involves data 
based on physicians’ working within each of the PSUs whose data is archived in the 
master files. The third stage probability sample includes random sampling of visits to 
physician offices.  The reporting period for each physician lasts about a week whereby 
either the physician or any office staff of physician collects information about patient’s 
socio demographics, specialty of physician, reasons for physician visit, method of 
payment for the physician visit, patient symptoms, diagnosis of patient symptoms, 
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complaints made by the patients, drugs prescribed by the physicians, first time or regular 
visit, preventive and therapeutic care provided of recommended.  The encounter between 
physician and patient or outpatient visit comprises the basic sampling unit in the NAMCS 
database. In order to calculate national estimates, each data record is inflated using an 
inflation factor known as the patient visit weight. This weight helps researchers to 
determine the overall office visits that took place in US. There might be some sampling 
variability observed. However, an estimate is deemed reliable by NCHS standards if the 
relative sampling error is less than 30% of the estimate. 
According to the inclusion criteria, the study sample of this study consisted of 
children aged 0 – 18 years with a current diagnosis of asthma (ICD-9 code 493.XX) and 
the mentioned of the word ‘asthma’ in the office visit who were a part of the 2007 
NAMCS (latest round available at the time of analyses). Patients with co-morbid 
conditions that confounded the study findings such as cystic fibrosis were excluded from 
the analysis. 
 
Covariates and Measures 
The primary dependent variable was the specific drug classes used in the 
management of asthma with a view of examining predictors of physician prescribing of 
controller versus reliever medications in children with asthma.  These drugs were 
classified on the basis of their role in the management of asthma and fall into the general 
categories listed in following Table 4.1. 
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Table 4.1 Drug Classes in the Pharmacotherapy of Asthma 
Controller Medication (CM) Reliever Medication (RM) 
Inhaled Corticosteroids (ICS) Short Acting Beta Agonist 
bronchodilators (SABA) 
Oral Corticosteroids (OC) Oral Corticosteroids (OC)* 
Long Acting Beta Agonist 
inhalers (LABA) 
Oral Short Acting Beta 
Agonists (OSABA) 
Leukotriene Modifiers 
(LM) 
Oral Short Acting 
Xanthines (OSAX) 
Inhaled Cromones (CI) Anti-Cholinergic 
Bronchodilators (ACB) 
Oral Long Acting beta 
Agonists (OLABA) 
Combination of SABA and 
ACB (BAACB) 
Oral Long Acting 
Xanthines (OLAX) 
 
Combination of LABA and 
ICS (LABIC) 
 
Notes: *The issue of the oral corticosteroid (OC) class in the analysis was  
             complicated. Based on the nature of the NAMCS dataset, the drugs  
 were categorized into the CM and RM group. 
This study used the Eisenberg physician decision making model as the structural 
framework for variable selection. According to this model, the physician decision making 
is influenced by four social factors:  (1) physician characteristics; (2) patients 
characteristics; (3) physician as a part of the health care system; and (4) physician’s 
relationship with the patient.  Physician characteristics included specialty, age, gender 
and type of practice which could influence their prescribing decisions. Previous studies 
have found associations between physician characteristics and prescription of certain 
medications such as leukotriene modifiers and theophylline (Blanc 2003; Ma 2005). 
Another study by Janson, et al showed that specialty physicians (such as respiratory 
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specialists) were more aware of asthma guidelines, and used evidence–based techniques 
to diagnosis, monitor and treat asthma (Janson and Weiss 2004).  Studies have also 
shown that patient characteristics such as age, gender, educational level, insurance status 
and socioeconomic status. Influence prescribing decisions.  Patients with lower 
socioeconomic status were shown to receive less optimal asthma emergency department 
care (Mvula et al. 2005). A study on Texas Medicaid enrollees found that emergency 
department visits and the rates of hospitalization was more than twice in pediatric 
patients compared to adults (Smith, Rascati, and Barner 2005).  
The physicians’ relationship with the healthcare system may also drive asthma 
care. A study showed that physicians working for an HMO specifically for a Preferred 
Provider Organization (PPO) were less likely to prescribe  leukotriene modifiers to their 
patients compared to physicians working with other insurers (Blanc 2003). Another study 
examining asthma medication prescribing and healthcare utilization among pediatric 
population enrolled in Managed Care Organizations (MCOs) found that about less than 
40% of the pediatric population was being prescribed controller medications compared to 
reliever medications (Donahue et al. 2000). The physician's relationship with the patient 
may influence physician prescribing, by patient/caregivers demands and symptom 
description.  A systematic review has found that effective patient physician interaction 
influenced physician’s decision making which in turn led to better health outcomes 
(Stewart 1995).  According to the Eisenberg’s model, patient physician interaction is 
classified into 3 categories: a) “activity passivity” where decisions are made primarily by 
physician and patients follow the decisions blindly, b) "guidance cooperation" where the 
physician guides the patient and the patient accepts the physician’s advice and c) "mutual 
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participation" where both the  patient and the physician participate and come to a mutual 
agreement (Eisenberg 1979). This model included different factors that influence 
physician decision making for prescribing anti-asthma medications. This model was also 
suitable for selecting independent variables for the study.  Hence this model proved as a 
favorable choice for this study. 
The dependent variables of the study were physician prescribing of anti asthmatic 
medication and the type of anti-asthmatic medication prescribed. The dependent variables 
are taken from the NAMCS prescription data and classified as per the prescribed 
medications listed in Table 1.1. Sociodemographic characteristics of the children 
included age, gender, race/ethnicity, and payment structure. Ethnicity was classified as 
Hispanic and non Hispanic. The payment structure is classified by method of payment 
(capitation/no capitation) and by percentage of financial incentives from P4P. All the 
measures of the independent variables are summarized in Table 4.2. 
 
Table 4.2 Study Covariates 
1. Physician Characteristics 
    Provider: Pediatrician Non-Pediatrician 
3. Physician’s Relationship with the 
Health Care System 
    Ownership status: Owner of solo 
practice 
      Owner of non-solo practice, Non-
owner 
    Geographic region of practice: 
      Northeast, Midwest, South, West 
    Metropolitan area: yes   
    Financial incentives: % of bonus 
2. Patient Characteristics 
    Gender: male 
    Age 
    Race/ethnicity: White, Black, Hispanic  
Capitated payment: yes 
4. Physician’s Relationship with the 
patient 
    Patient see before: yes 
    Asthma is the primary diagnosis listed  
    for the visit: yes 
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           One of the limitations of NAMCS is that it provides limited information about 
physician characteristics. Among physician characteristics, it includes the physician 
specialty categorized as pediatricians and non-pediatricians. Physician’s relation with the 
healthcare system is characterized by his geographic location of practice (Northeast, 
Midwest, South and West, metropolitan and non metropolitan areas) and physician’s 
ownership of practice (solo, non solo and non owner). Patient physician relationship was 
categorized by first or routine visit and if asthma was the primary cause of physician 
visit. 
 
Statistical Analysis 
           The sample consisted of 1041 children with current asthma diagnosis aged 0-18 
years and was classified under two categories, ie, ever been told they had asthma and still 
had asthma. These 1041 observations represented a total of 35,043,953 weighted visits 
related to asthma for the year 2007 in US outpatient settings. Chi-squared tests were used 
to examine bivariate associations between the predictor variables and the uses of control 
medication only, reliever medication only, as well as both.  
 Multivariate analyses were also conducted in order to examine the effects of 
financial incentives on asthma-related medication use among children with asthma, using 
separate logistics regression analyses and simultaneously controlling for physician/patient 
characteristics, physician’s relationship with the health care system and physician’s 
relationship with patients. All odds rations (OR) and P values were reported.  
 Weighting was used in the NAMCS dataset to measure collective statistics 
representative of the entire population. In particular, sample weighting compensated for 
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differences in probabilities of sample selection and differences in the sampling rates of 
the persons interviewed. Weighting also reduced any bias arising from different 
characteristics of respondents and nonrespondents. Weighting reduced variance among 
the data collected, as well as compensating for undercoverage of the sample population 
while administrating the survey. The sample weights (‘patient visit weigit’) used for 
statistical analysis in the study created by NAMCS. 
 The following were descriptions of the model for this study: 
Pr [Y [Only Controller Medication prescribed] = 0 or 1] 
= f [ß0 + ß1 (patient factors) + ß2 (physician factors) 
+ ß3 (physician - health care system interaction factors) 
+ ß4 (physician - patient interaction factors)] + e 
 
where Y = 0 if no controller medication is prescribed, Y = 1 if controller medication is 
prescribed; f(•) is the cumulative density function (CDF) of logistic distribution and e is 
the error term. 
Pr [Y [Controller & Reliever Medications (both) prescribed] = 0 or 1] 
= f [ß0 + ß1 (patient factors) + ß2 (physician factors) 
+ ß3 (physician - health care system interaction factors) 
+ ß4 (physician - patient interaction factors)] + e 
 
where Y = 0 if no medication is prescribed, Y = 1 if both medications are prescribed; f(•) 
is the cumulative density function (CDF) of logistic distribution and e is the error term. 
Pr [Y [Only Reliever Medication prescribed] = 0 or 1] 
= f [ß0 + ß1 (patient factors) + ß2 (physician factors) 
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+ ß3 (physician - health care system interaction factors) 
+ ß4 (physician - patient interaction factors)] + e 
 
where Y = 0 if no reliever medication is prescribed, Y = 1 if reliever medication 
prescribed; f(•) is the cumulative density function (CDF) of logistic distribution and e is 
the error term. 
 
Results 
 Table 4.3 presents the descriptive statistics of the children being seen for asthma. 
A total weighted number of 35,043,953 subjects (unique patient visits) were examined for 
the year 2007. The mean age of asthmatic children in the sample was 8.7 years (range 
from 1 to 18). There were more female (56%) compared to male subjects. A majority of 
the study population comprised of non-Hispanic white (82%) asthmatic patients. More 
than half of the study population (62%) was covered by private insurance for their 
asthma-related healthcare. Around one-third patient (34%) asthma related visits were 
capitated. More than two-thirds of physician received the medium or high financial 
incentives from payer (87%).  A majority of physicians (88%) practiced in metropolitan 
areas. In 86% of the visits, asthma was listed as the primary reason for the outpatient 
visit.  
[Table 4.3 goes about here] 
Table 4.4 presents the weighted logistic regression results examining predictors of 
the type of anti-asthmatic medications prescribed. The weighted odds ratios (OR) and the 
95% confidence intervals are reported in Table 4.4.  First we examined whether factors 
that predicted whether patients received a controller medication differed compared to 
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those receiving reliever medications only or both medications. Patients age 5-18 years 
were significantly more likely to be prescribed the controller medication than reliever 
medication compared to age 1-4 years (71%, p<0.01). Patients seeing a pediatrician were 
approximately 69% more likely than patients seeing a family doctor to receive a 
controller medication than reliever medication (p<0.01). Patients covered by capitated 
plans were 23% more likely to receive controller medications than reliever medications 
(p<0.01). Patients belonging to the Hispanic race were 28% less likely to receive 
controller medication compared to Non-Hispanic White (p<0.05) subjects. Compared 
with physicians who received the lower financial incentives, the physicians who received 
medium (39%, p<0.05) or high (42%, p<0.01) financial incentives from payers were 
more likely to prescribe controller medication than reliever medication. 
 Next we examined which factors influenced whether patients received a reliever 
medication compared to those receiving both a controller and reliever medication. 
Patients seeing a pediatrician were approximately 67% less likely than patients seeing a 
family doctor to receive a reliever medication. Patients aged 5-18 years were significantly 
less likely to receive the controller medication (47%, p<0.01). Physicians who received 
medium (35%, p<0.05) or high (30%, p<0.05) financial incentives were significantly less 
likely to prescribe the reliever medication to children. Patients in the Midwest were 
significantly less likely than patients in the west to receive the reliever medication (71%, 
p<0.05).   
[Table 4.4 goes about here] 
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Discussion 
 The Eisenberg model of physician decision making has been widely used to 
characterize physician decision making, physician prescribing and the sociological 
factors that influence physician decision making (Tamblyn et al., 2003; Leffler 1981). In 
this study, the model was used to study the sociological factors that influence physician’s 
behavior concerning the adoption of financial incentives and prescription of anti-
asthmatic medication in children. The factors that could potentially influence physician 
behavior are: (1) physician characteristics (e.g. age, gender, race, specialty); (2) patient 
characteristics (e.g. age, gender, race, educational level, insurance status, income); (3) 
physician's relationship with the health care system (e.g. practice setting, ownership); and 
(4) physician's relationship with the patient (e.g. patient demand, patient presentation of 
symptoms) (Eisenberg 1979). There were several strong associations found between 
these characteristics and prescribing that could have great interest for policymakers.  
 In terms of patient characteristics, children whose outpatient visits were covered 
by public insurance (like Medicare & Medicaid) were more likely to receive the reliever 
medication compared to publicly insured patients. This suggests that asthmatic children 
with public health insurance may not be receiving appropriate controller anti-asthmatic 
medication that could improve their asthmatic symptoms and quality of life. Also from 
the study results, Hispanic children with asthma were less likely to receive controller 
medication for asthma treatment. Another patient characteristic that influenced 
prescribing was patient age. Patients aged 5-18 years were significantly more likely to 
receive a controller medication than reliever medication than patients age 1-4 years. This 
finding could suggest both stabilization of asthma symptoms with increasing age that 
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require controller medications, as well as reluctance on the part of physicians to use 
corticosteroids in very young asthmatic patients.  
 Physician specialty was significantly related with prescribing controller 
medication for asthmatic children. Patients whose providers were a pediatrician were 
more likely to receive controller medication compared to patients seeing family 
physicians. These findings also suggest that pediatricians are being visited by patients for 
getting asthma treatment which might involve multiple medications. Also, patients in 
whom single medication therapy has failed, comprise more complicated cases and could 
more likely to visit their pediatricians for getting asthma care. 
 The physician’s relationship with health care system also influenced anti-
asthmatic medication prescribing. An import finding of this study is that physicians who 
had medium or high financial incentives from insurance plans or payers were about 40 % 
more likely to prescribe a controller medication. Asthma “controller” drugs are used to 
reduce inflammation and are the most import component of long-term control in children 
with mild or severe diseases. In clinical practice, the ratio of controller medications to 
total asthma medications has proven to be a quality-of-care measure used frequently in 
asthma. A controller to total asthma medication ratio of .5 or more may be more 
reflective of adequate asthma quality of care (Schatz 2004). Finally, we found that 
patients in the Midwest and Northeast were more likely to receive a reliever medication 
than just a controller medication than patients in the West. These geographical variations 
in physician prescribing could be due to differences in: (a) physician adoption of 
prescribing guidelines, and (b) cultural norms in the physicians’ respective practice areas. 
Future research is needed to better understand these geographical differences. 
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 This study has several limitations. First, since we used a public access database 
(NAMCS), it does not provide all the relevant physician and patient variables which may 
affect prescribing behavior. Second, we do not know the exact severity of a child’s 
asthma in this database so we could not control for this when examining which subjects 
receive an anti-asthmatic medication and what types of anti-asthmatic medication they 
received. Third, the database is based on self-report of physician and their staff and 
therefore it may be subject to some recall bias. Fourth, the study database does not 
provide health care utilization such as ER visit and Inpatient visits and outpatient patients 
may not represent the most severe asthma cases. Finally, the NAMCS database lacks 
specific variables that explain the impact of medication adherence and self-monitoring 
behaviors, as well as variables examining barriers to physician guideline adherence. 
 Even though there were some limitations of our study, our results indicate that 
all four domains (patient characteristics, physician characteristics, the physician’s 
relationship with the health care system, and the physician’s relationship with the patient) 
that could influence physician care influence anti-asthmatic medication prescribing in 
children in the United States. Our results also indicate that provider pharmaceutical care 
in public insured children as well as other underserved populations such as ethnic 
minorities is needed so that these children can receive better asthma treatment and in 
turn, have improved quality of life. 
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Table 4.3 Descriptive Statistics of the Children being seen for Asthma 
Variables % or mean 
Provider Characteristics 
   General practitioner/Family medicine 
   Internal Medicine 
   Pediatrics 
   Pulmonary specialties 
   Other 
Patient characteristics 
   Gendar: Male 
   Age  
 Race/ethnicity: 
   Non-Hispanic: White 
   Non-Hispanic: Black 
   Hispanic: 
   Other 
 Primary source of payment 
   Private insurance 
   Public insurance (Medicare & Medicaid) 
   Other 
 Capitated visit: yes 
 Patient belong to HMO: yes 
 Capitated HMO 
Taking  Anti-asthmatic medication: yes 
Physician’s Relationship with Health Care System 
 Incentive Status: 
Lower financial incentives 
Medium financial incentives 
Higher financial incentives  
Ownership status: 
Owner of solo practice 
Owner of non-solo practice 
Non-owner 
Geographical area 
MSA 
Non-MSA 
Geographic region 
Northeast 
Midwest 
South 
West 
Physician’s Relationship with Patient 
 Patient seen before 
 Asthma is primary diagnose 
 
20 
14 
27 
34 
4 
 
44 
8.7 (mean) 
 
82 
7 
9 
2 
 
62 
27 
11 
34 
11 
4 
68 
 
 
13 
49 
38 
 
53 
19 
28 
 
88 
12 
 
27 
19 
33 
21 
 
89 
86 
N (weighted) = 35,043,953 
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Table 4.4 Odds ratios for anti-asthmatic medication use using logit models 
 
  Controller only  Reliever only  Both 
Variable Weighted OR 95% CI 
Weighted 
OR 95% CI 
Weighted 
OR 95% CI 
Provider Characteristics 
   Family medicine 
   Internal Medicine 
   Pediatrics 
   Pulmonary specialties 
   Other 
Patient characteristics 
   Gendar: Male 
   Age: 1-4 
   Age: 5-18  
 Race/ethnicity: 
   Non-Hispanic: White 
   Non-Hispanic: Black 
   Hispanic: 
   Other 
 Primary source of payment 
   Private insurance 
   Public insurance  
   Other 
 Capitated visit: yes 
 Patient belong to HMO: yes 
 Capitated HMO 
Taking  Anti-asthmatic  
 medication: yes 
Physician’s Relationship with 
Health Care System 
 Incentive Status: 
Lower financial incentives 
Medium financial incentives 
Higher financial incentives  
Ownership status: 
Non-owner 
Owner of solo practice 
Owner of non-solo practice 
Geographical area 
Non-MSA 
MSA 
Geographic region 
West 
Northeast 
Midwest 
South 
Physician’s Relationship with 
Patient 
 Patient seen before 
 Asthma is primary diagnosis 
 
Ref 
0.64 
1.69** 
1.12 
1.07 
 
1.00 
Ref 
1.71** 
 
Ref 
1.12 
0.72* 
0.57 
 
Ref 
0.94* 
0.64 
1.23** 
1.41 
1.16 
0.75 
 
 
 
 
Ref 
1.39* 
1.42** 
 
Ref 
0.85 
1.21 
 
Ref 
1.31 
 
Ref 
0.85 
0.82 
1.01 
 
 
1.15 
0.71 
 
 
(0.18, 1.24) 
(1.23, 2.34) 
(0.56, 3.98) 
(0.39, 2.91) 
 
(0.46, 1.27) 
 
(1.16,2.32) 
 
 
(0.46, 3.69) 
(0.49, 0.87) 
(0.11, 1.96) 
 
 
(0.56, 0.99) 
(0.28, 1.38) 
(1.02, 1.73) 
(0.71, 2.79) 
(0.35, 3.49) 
(0.51, 1.13) 
 
 
 
 
 
(1.03, 1.89) 
(1.12, 2.17) 
 
 
(0.53, 1.39) 
(0.67, 2.09) 
 
 
(0.70, 2.45) 
 
 
(0.51, 1.37) 
(0.42, 1.61) 
(0.64, 1.67) 
 
 
(0.49, 2.66) 
(0.35, 1.46) 
 
Ref 
1.05 
0.33** 
0.77 
1.01 
 
1.36 
Ref 
0.53** 
 
Ref 
1.36 
1.42* 
1.95 
 
Ref 
1.17* 
1.41 
0.62* 
0.64 
0.61 
0.78 
 
 
 
 
Ref 
0.65* 
0.70* 
 
Ref 
0.67 
1.21 
 
Ref 
0.61 
 
Ref 
0.43 
0.29* 
0.52 
 
 
1.00 
1.04 
 
 
(0.49, 1.91) 
(0.22, 0.49) 
(0.46, 1.27) 
(0.27, 2.08) 
 
(0.89, 2.06) 
 
(0.36, 0.76) 
 
 
(0.43, 3.32) 
(1.04, 2.16) 
(0.38, 3.76) 
 
 
(1.05, 4,59) 
(0.35, 5.69) 
(0.38, 0.99) 
(0.27, 1.53) 
(0.16, 2.31) 
(0.45, 1.32) 
 
 
 
 
 
(0.43, 0.99) 
(0.49, 0.64) 
 
 
(0.39, 1.15) 
(0.66, 2.26) 
 
 
(0.22, 1.65) 
 
 
(0.24, 1.98) 
(0.29, 0.85) 
(0.16, 1.57) 
 
 
(0.99, 1.01) 
(0.48, 2.41) 
 
Ref 
0.67 
0.46** 
0.84 
1.08 
 
1.69 
Ref 
0.56** 
 
Ref 
0.71 
1.45* 
1.01 
 
Ref 
1.22 
1.13 
0.74* 
0.41 
1.31 
0.77 
 
 
 
 
Ref 
0.74* 
0.61** 
 
Ref 
0.79 
1.12 
 
Ref 
1.01 
 
Ref 
0.57* 
0.71 
0.67 
 
 
0.88 
0.94 
 
 
(0.19, 2.18) 
(0.34, 0.63) 
(0.57, 1.94) 
(0.39, 2.95) 
 
(0.84, 3.41) 
 
(0.40, 0.81) 
 
 
(0.14, 3.59) 
(1.12, 1.78) 
(0.31, 2.17) 
 
 
(0.72, 2.24) 
(0.59, 2.11) 
(0.54, 0.98) 
(0.21, 1.83) 
(0.84, 2.16) 
(0.51, 1.23) 
 
 
 
 
 
(0.54, 0.92) 
(0.35, 0.89) 
 
 
(0.47, 1.36) 
(0.61, 2.01) 
 
 
(0.53, 1.92) 
 
 
(0.34, 0.97) 
(0.39, 1.36) 
(0.48, 1.29) 
 
 
(0.49, 1.76) 
(0.38, 1.72) 
*: p<0.05 **: p<0.01 
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2 CHAPTER 5 
CHAPTER 5 
DISSERTATION MANUSCRIPT #2: PHYSICIAN PAYMENT INCENTIVES 
AND ASSOCIATED HEALTHCARE UTILIZATION OUTCOMES IN 
MEDICAID ENROLLED ASTHMATIC CHILDREN 
 
ABSTRACT 
 
The purpose of this retrospective cohort study was to examine associations between the 
type of health plan (fee for service vs. capitated) and utilization-based outcomes (health 
care services and medication adherence) in asthmatic Medicaid children. Subjects were 
6435 Medicaid enrolled asthmatic children who newly started asthma controller 
pharmacotherapy and were followed 12 months before and 12 month after the index anti-
asthmatic medication.  Data was collected on health care utilization and medication 
adherence was calculated from the Medicaid Marketscan® database for the years 2005-
2007. Quantile regression analysis was used to examine predictors of medication 
adherence while poisson regressions were used to examine incidence of health care 
service utilization. Patients in FFS plan had significantly associated with higher 
medication adherence rates (p<0.01) compared to those in capitated plans. Moreover, 
patient in capitated plans were associated with 77% more inpatient hospitalizations and 
34% increased incidence rates of emergency department visits, but 42% fewer outpatient 
visits compared to those in FFS plans (all p<0.05). Although Medicaid programs use 
capitated managed care plans primarily as a cost-containment strategy, these plans may 
not be cost-effective for the long-term management of asthma.  
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Introduction 
Asthma is a chronic respiratory disease characterized by episodes or attacks of 
inflammation and narrowing of small airways in respiratory system (NCHS, 2005). Some 
of the most established measures of prevalence of asthma are Center for Diseases 
Control’s (CDC) Behavioral Risk Factor Surveillance Survey (BRFSS) and the National 
Health Interview Survey (NHIS) (CDC 2007; NCHS 2005). Estimates of the lifetime 
prevalence of asthma among adults have ranged from 10-12% over the past 6 years while 
current asthma for adults is generally reported at approximately 7-8% (Mannino 2002). 
National estimates suggested that lifetime asthma prevalence for children less than 18 
was approximately 12.5% with age specific prevalence of 7.5, 14, and 14.7 percent for 
children aged 0-4, 5-11, and 12-17 respectively (CDC 2005). 
Poor and minority children bear a disproportionate share of the population burden 
of asthma. This is reflected in higher rates of hospitalization and emergency room visits 
for asthma, lower utilization of pharmaceutical agents known to improve control of 
asthma, higher prevalence and severity of the disease, lower rates of utilization of 
primary care services related to asthma (Akinbami et al. 2009; Akinbami and Schoendorf 
2002; Ash 2005; Dougherty 2005; Gold and Wright 2005; Krishnan 2001; Lieu et al. 
2002; Weiss, Sullivan, and Lyttle 2000). These trends have been attributed to the 
characteristics and financing of the US medical care system and their associated impact 
on access to medical care (Bindman 1995; Friedman 2001; Homer 1996) and to 
individual characteristics of the population (Lynch 1997). 
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Poor children are more vulnerable to poor health in general because they are apt 
to have multiple risk factors (Aday 2001; Chang et al. 2011). Investigation of single risk 
factors is useful but perhaps does not reflect the real-world scenarios where risk factors 
often cluster, e.g., low education and low income (Min, Chang, and Balkrishnan 2010; 
Patel et al. 2010; Stevens et al. 2006). Previous research has suggested that multiple risk 
factors may produce an additive impact on children's mental, physical, and social health 
and school performance (Starfield, Robertson, and Riley 2002; Stevens et al. 2006) 
especially in conditions such as asthma (Wood 2002). 
One of the key components in long-term control of asthma is pharmacotherapy, 
and the present study is focused on whether children received recommended medication 
by the guidelines of National Asthma Education and Prevention Panel (NAEPP) through 
the analysis of the Medicaid pharmacy data.  According to the NAEPP report (1997), the 
most effective long-term control medication for asthma was the corticosteroid inhaler. 
Several studies confirm that the daily use of steroid inhalers greatly reduce asthma 
symptoms, occurrence of severe exacerbations, use of quick-relief medications, and lung 
function measured by peak flow, FEV and airway hyper responsiveness (Cloutier et al. 
2005; Cochrane 1999). 
Several factors affect patient adherence to medications. Insurance coverage/type 
of health plan plays a key role in providing access to essential health care services. With 
no or limited insurance coverage, patients who use more drugs face increasing out-of-
pocket costs, which may result in decreased adherence (Janson and Weiss 2004; Jansson 
et al. 2007). Access to pharmaceutical innovation is also mediated by the patient’s 
primary source of health insurance coverage. Patients with public insurance (Medicare 
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and Medicaid) are less likely to receive newer medications for the management of 
chronic diseases (Cloutier et al. 2005). 
From its inception, the Medicaid program's costs had exceeded estimates (Freund 
and Hurley 1995). Congress authorized waivers to state Medicaid plans in 1981 that 
made it possible for states to experiment with managed care as a means to control costs 
(Stevens et al. 2006). States commonly implemented one of two types of Medicaid 
managed care plans: 1) Capitation (pre-paid) and 2) Fee-For-Service (Kaye 2005). Under 
the capitation or prepaid model, the managed care organizations (MCOs) got payment on 
a capitated basis (fixed payment) to deliver health care. Data are lacking on health 
outcomes for patients with chronic conditions (eg, asthma) in capitated plans in the 
Medicaid population (Karnick et al. 2007; Kozyrskyj, Mustard, and Becker 2003; Lara et 
al. 2003; Wagner 2005). Particularly, the effect of type of health plan (such as capitation) 
on medication adherence and health care service utilization on asthmatic children is 
unknown. Taking into account the limited amount of health care resources and growing 
health care expenditures, examining the effect of type of health plan on outcomes will be 
helpful to policy makers to make informed decisions regarding appropriate adoption of 
reimbursement policies and effective allocation of limited health care resources for this 
vulnerable population. Hence, the primary objective of this study was to examine the 
association between type of health plan (FFS vs. capitated) and economic outcomes 
(health care utilization and medication adherence) in asthmatic Medicaid-enrolled 
children. 
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Materials and Methods 
This study used the MarketScan® Medicaid claims dataset licensed from 
Thompson Medstat. It consisted of the data from 8 different states of varying size and 
dispersed all across the U.S (MarketScan® research database, 2008). The states are de-
identified; however, data consist of at least one state from each U.S. region. The database 
consisted of medical (outpatient and inpatient services), drug, and long-term care claims 
and eligibility records for enrollees from these states. The prescription drug coverage was 
provided by all the states. The data were available from 2005 to 2007 representing around 
5.4 million individuals in the United States (MarketScan® research database, 2008). For 
the purpose of this study, the Medicaid database were updated and queried from January 
1, 2005 to December 31, 2007. The database was HIPPA compliant and features 
encrypted member and service provider identification numbers. The data from these 
states provided a fairly large sample of the Medicaid enrollees in the U.S. The dataset 
also provided additional information on variables such as race/ethnicity, Medicare 
eligibility and Medicaid eligibility / federal aid category.  
The study population comprised of children aged 0 to 18 years of age. The 
patients with a diagnosis of asthma and a prescription of a new asthma medication 
(Inhaled Bronchodilator, Anti-Inflammatory, Systematic Bronchodilator, Systematic 
Corticosteroid and/or Leukotriene Modifiers) during the study time period included. 
Subjects with a primary or secondary diagnosis of asthma identified using the 
International Classification of Diseases Code 9th Revision (ICD-9: 493.XX) from claims 
data during the study test period. Only subjects who have maintained continuous 
eligibility for 1 year period between January 1, 2005 and December 31, 2005 included in 
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the study. The date for the first prescription claim for anti-asthmatic medication use 
designated as an index date, where the medication identified using relevant National 
Drug Codes (NDC) recorded in the claim records. The study required all patients to have 
continuous health plan enrollment for at least 1 year prior to and following their index 
date. This was to ensure that each patient’s index date presents a reasonable marker for 
treatment initiation as well as making sure that any observed lack of health care events 
was due to a lack of medical activity and not due to cessation of insurance. The 
identification period ranged from January 1, 2006 to December 31, 2007. During this 
time period, any patients who have an asthma diagnosis and who were prescribed an anti-
asthmatic medication were included. 
 
Measurement and Outcomes 
The operational definitions and measurements of the variables utilized in this 
study discussed in this section. The dependent variables for this study are medication 
adherence, hospitalizations, emergency room (ER) visits and asthma-related healthcare 
costs. The independent variables tested in this study are payment mechanisms (capitated 
vs. fee for service). Other independent covariates include age, gender, access to specialty 
care, and disease severity. The operational definition of each variable described in the 
following sections: 
 
Medication adherence 
Medication adherence signified medication usage by patients. It was basically the 
act of conforming to the physician’s recommendations about the timing, dosage, and 
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frequency of medication intake.  The International Society of Pharmacoeconomics and 
Outcomes research defined medication adherence as the extent to which a patient 
complies with the intended dosing regimen (Hess 2006). The unit of measure for 
compliance was administered doses per defined period of time, reported as a proportion 
(%) of prescribed doses (D) taken at the prescribed time interval (T) as measured by the 
period of time.  
Medication adherence can be measured directly and indirectly by utilizing 
biological markers, blood and urine assays, patient interviews, pill counts, prescription 
refills, and electronic monitoring (Claxton, Cramer, and Pierce 2001; Hess 2006). Since 
the study uses an insurance claims database, prescription refill patterns can be used to 
capture medication adherence. The information thus obtained records the frequency and 
timeliness of refills of prescribed medication and eliminates any Hawthorne effect. Also 
pharmacy records had predictive validity as measures of cumulative exposure and gaps in 
medication supply (Steiner 1998). On the other hand this method also had some 
limitations like presence of data on unusual refill patterns, multiple conflicting drugs and 
inability to capture all data about patients visiting multiple pharmacies. Also utilization of 
pharmacy records assumes that “a prescription filled is a prescription taken” (Balkrishnan 
2005). The data cannot measure actual consumption but only estimates about actual 
medication consumption (Hess 2006). 
Medication adherence in this study indicated patient’s intake of anti-asthmatic 
prescription medication. Data from the pharmacy claims database can be used to measure 
medication adherence by several ways. Medication possession ratio (MPR) is one such 
measure used to calculate medication adherence. For the purposes of this study, MPR is 
  88
calculated as the days of anti-asthmatic medication supply dispensed divided by the 
number of days in the observation period (#365) minus the number of days in the hospital 
(Camargo 2007; Hess 2006; Sokol et al. 2005). Previous studies have shown that 
medication adherence measurement for the entire study period which is 365 days in this 
study, when used as a denominator, predicts hospitalization and healthcare costs in a 
more appropriate manner compared to adherence measures considering the period 
between the first and last refill (Camargo 2007; Mattke et al. 2010). Medication 
adherence measures like MPR, proportion of days covered (PDC), Continuous 
Medication Gap (CMG) and Continuous Multiple interval of Oversupply (CMIOS), 
Medication Refill Adherence (MRA) use the entire study period as a denominator. Also 
measures like Refill compliance rate (RCR), compliance rate (CR), and modified 
medication possession ratio (MPRm) which measure the period between the first and last 
refill lack a consistent denominator value while calculating adherence (Hess 2006). The 
above measures fail to account for early medication discontinuation, thereby 
overestimating adherence for patients stopping their medication intake when they should 
be taking it. Therefore, MPR for this study is defined as  
MPR= # of days supply of anti-asthmatic medication in the post-index period / # of days 
in the study period (365 days).  
 
The observation period in this study included the post-index period or 12 month 
follow up period which was consistent for each patient. The number of hospital days was 
subtracted from the denominator because any drug taken during this period was given to 
the patient by the hospital and was not possible to capture in the pharmacy records. The 
information on each filled prescription included of dispensing, quantity dispensed, and 
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days’ supply of medication. Medications used were placed into 2 categories: asthma 
controller medications and reliever medications. Controller medications consisted of ICSs, 
ICSs/LABAs, LABAs, LTRAs and theophylline. Reliever medications included short-
acting β-agonists (SABAs) and systemic corticosteroids. We examined the distribution of 
the day of supply for the asthma medications, summing for each patient the number of 
days supplied by their prescriptions for the 365 days of follow-up.  The MPR was 
calculated for any asthma medication possession on a given day of the year and avoided 
double counting of multiple asthma medication use on the same day by the same patient.  
 
Healthcare Service Utilization 
Patients were followed during pre-index and post-index period (i.e. 12 month 
before and 12 months after the index date) to assess their healthcare utilization in terms 
of hospitalizations, ER visits, outpatient visits. Variables related to hospitalizations, ER 
visits and outpatient visits were used as a proxy for health care service utilization. To 
identify hospitalizations in patients, their admission and discharge dates recorded in 
inpatient service files are used. CPT codes as well as service codes were taken from the 
inpatient and outpatient services files for identifying events of ER visit and outpatient 
visits. 
 
Sociodemographic variables 
The following sociodemographic variables were taken from the Medicaid data: 
gender, birth year and race/ethnicity. The gender of the patients was categorized into 
males and females. Birth year of the patients was used to calculate their age. Race or 
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ethnicity of patients was classified as whites, blacks, Hispanics and others. The Medicaid 
dataset also had information about the health plan (capitated or fee for service) that 
patients were enrolled in. 
 
Proxy for asthma severity 
Based on the established relationship between disease severity and intensity of 
treatment, severity of a condition in the current period was inferred by a risk of an 
exacerbation in a future. Some of the independent predictors widely used in the literature 
for ascertaining future asthma-related emergency hospital utilization (EHU) are 
hospitalizations, use of emergency department and use of oral corticosteroids (Roth 2004; 
Schatz 2004). Severity of asthma in the current period is assessed by determining high 
risk of EHU. Risk stratification schemes are developed using pharmacy claims or facility 
claims or a combination of both.  Combination of pharmacy and facility claims are more 
successful in stratifying risk compared to using pharmacy or facility claims single-
handedly (Roth 2004; Schatz 2004).    A popular type of risk stratification scheme used is 
a simple three-level risk stratification (Table 5.1) which ranks risk of future EHU based 
on a point system applied to a period of current utilization. Points are assigned to 
different indicators of future asthma related EHU. Asthma hospitalizations or ED 
encounters in the 12-month base period are assigned 2 points, 15 or more beta-agonist 
canisters in the base period are assigned 1 point and 1 or more filled prescriptions for oral 
corticosteroids are assigned 1 point. Members are differentiated on the basis of 
assignment of points. Members with 2 or more points, 1 point and 0 point are classified 
as high risk, medium risk and low risk groups respectively (Schatz 2004). 
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Table 5.1 Three-Level Risk Stratification of Asthma Severity 
 
Event per 12-
month base period 
Potential Point 
Assignment 
Low Risk 
0 Points 
Medium Risk 
1 Points 
High Risk 
2 or more Points 
A. ED visits   
     asthma  
     encounter 
2 0 0 2 
B.  IP visits  
      asthma  
      encounter 
2 0 0 2 
C. 15 or more  
     beta-agonist  
     canisters  
     dispensed 
1 0 1 1 
D. Any oral  
     corticosteroid  
     prescriptions  
     dispensed 
1 0 1 1 
Required events for 
risk level 
 No listed events Either C or D Either A or B 
and/or C and D 
 
Therefore, the measurement of asthma severity is the probability of an asthmatic member 
having a risk score (severity proxy) of 0,1, or 2. 
Type of health plan (FFS vs. Capitation).  
The Medstat MarketScan® Medicaid database provides patient level indicator 
variable for the type of health plan enrolled for by each patient. Medicaid has classified 
plans into 2 groups (MarketScan® Medicaid database user guide, 2005):  
1. Capitation: represents capitated managed care plan where MCOs receive a fixed 
amount of payment per enrollee per month. All or some services offered by MCOs are 
paid on a capitated basis.  
2. Fee-for-service (FFS): indicates health plans that pay providers or physicians on the 
basis of services rendered. There is no incentive for the patient to use a particular list of 
providers. Coverage is handled by only one policy, with a deductible and coinsurance. 
The patient level variable is coded as 1 for capitation and 0 for FFS health plan. 
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Table 5.2 Analytical Framework and study covariates for Chapter 5. 
Target population: Children aged 0 to 18 years with a diagnosis of asthma receiving  
                                 care in a Medicaid Setting 
Outcomes: Medication Possession Rate, and Healthcare services utilization (ER, IP &  
                   OP),  
Regressor of interest: Health plans (FFS vs. Capitated)  
Covariates: 
Patient Characteristics: Patient’s age, gender, and race/ethnicity (Predisposing factors) 
Patient’s Medical Conditions: Asthma severity                             (Need factors) 
Physician Characteristics: Specialty                                              (Enabling factors)  
Asthma drug ratio: A controller to total asthma medication ratio of 0.5 or more 
 
Statistical Analysis 
Descriptive statistics were performed to compare baseline characteristics in the 
cohort of study patients. Continuous data were described by means and standard 
deviations, and nominal and categorical data were described by frequencies and 
percentages. Unadjusted demographic, clinical, and medication characteristic 
comparisons between groups were completed using independent sample t tests for 
evaluation of continuous variables and chi-square tests for categorical variables. The data 
were analyzed using STATA software version 10 (Stata Corp, College Station, TX). All 
univariate, bivariate, and multivariate analyses were conducted at a set a priori level of 
significance (0.05). 
Quantile regression was used to evaluate the relationship between the type of 
health plan and medication adherence after controlling for potential covariates. Quantile 
regression provided a convenient linear framework for examining how the quantiles of a 
dependent variable change in response to a set of independent variables using linear 
conditional quantile functions. The primary independent variable was the type of health 
plan (FFS vs. capitation). Other covariates included in the model were demographic (age, 
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sex, race/ethnicity), clinical variables such as severity index including health care 
resource utilization in pre-index period (hospitalizations, ER visits), and therapy-related 
variables (appropriate medication choice). The normality was determined using the 
Shapiro–Wilk test. The heteroskedasticity was determined using the White test. The data 
were also examined for multicollinearity (ie, a linear relationship between predictor 
variables). A variation inflation factor of <10 was considered to indicate absence of 
multicollinearity. 
Logistic regression model was used to predict the likelihood of healthcare 
utilizations (outpatient, inpatient, and ER visits). Also, the poisson regression model was 
used to model predictors of the frequency of healthcare utilizations (outpatient, inpatient, 
and ER visits) while the zero-inflated poisson regression model was used to predict the 
number of hospitalizations. The adequacy of model was examined using the Vuong test. 
The following were the description of the models for this study: 
MPR (Asthma Controller medication adherence-quantile regression) 
= ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (Capitated vs. FFS) + e 
Where MPR stands for the medication possession ratio to measure anti-asthmatic 
medication adherence, and e is the error term. 
Pr [Y [health care utilization] = 0 or 1] 
= f [ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (MPR) + ß6 (Capitated vs. FFS)] + e 
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where Y = 1 if some specific health care is utilized and Y = 0 if not; f(•) is the cumulative 
density function (CDF) of logistic distribution and e is the error term. 
Asthma-related healthcare utilization (a count variable, the number of visits) 
= ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (MPR) + ß6 (capitated vs. FFS) + e 
Where count model consists of poisson regression and negative binomial regression, e is 
the error term. 
 
Results 
The study cohort consisted of a total of 6435 children with asthma. The mean age 
of the cohort was 8.1 years (standard deviation [SD]: 6.7) and comprised 61.8% females 
(n=3966). The majority of children were white (49.8%) followed by black (43.8%); only 
6.3 percent were of Hispanic ethnicity. A total of 2607 (40.5%) children were enrolled in 
capitated health plans and the remaining children (59.5%) were enrolled in traditional 
FFS plans. 
 Bivariate analysis showed that the mean age of patients enrolled in capitated plans 
(7.5 years [SD: 6.4]) was a little lower than that of patients enrolled in FFS plans (8.7 
[SD: 7.1]; P<0.01). The proportion of females (62.5%) was slightly higher in capitated 
plans compared to FFS plans (61.2%; P<0.01). Capitated plans had a little lower 
percentage of black (43.4%) than FFS plans (44.3%; P<0.01). When medication 
adherence was examined, patients in FFS plans had a somewhat higher medication 
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possession ratio (45.49%) than those in capitated plans (34.72%; p<0.01). When we 
examined health care service utilization in the pre-index period, visits to pediatricians 
were somewhat higher in FFS plans than in capitated plans (77.7% vs. 75.9%; P<0.01). 
When compared to patients in capitated plans, patients in FFS plan had significantly 
higher MPR values (34.72 vs. 45.49, p<0.01). The number of ER visits were much higher 
in capitated plans compared to FFS plans (76.0% vs. 46.4%; P<0.05); however there was 
no significant difference in number of hospitalizations. 
[Table 5.3 goes about here] 
 Table 5.4 shows the comparison of medication adherence rates to asthmatic 
medication in asthmatic children across the health plans. Quantile regression analysis was 
conducted to measure the association between the type of health plan and medication 
possession ratio. The dependent variables were two quantile points (40% vs. 80%) which 
indicated low and high rates of medication adherence. In the case of quantile 40% of 
medication adherence, there were several factors associated with medication adherence. 
First, female, African American Race, and being Hispanic were negatively associated 
with medication adherence rates of quantile 40% (p<0.05). Second, asthma drug ratio 
(ratio of controller to total medication) was negatively associated with medication 
adherence rates (p<0.01). Third, total expenditure was positively associated with 
medication adherence rates (p<0.01). There was no significant difference in adherence 
between severity index, age, and total number of prescriptions. 
 We also evaluated the effect of the type of health plan on medication adherence 
rates on quantile 80%. There were several factors that influenced on medication 
adherence of 80%. First, patients with capitated plans had negatively associated with 
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medication adherence of 80% (p<0.01). Second, patients aged 5-18 years had positive 
associations with medication adherence rates of 80%. Third, patients belonging to 
African American race or Hispanic ethnicity were negatively associated with higher 
medication adherence. Fourth, patients with more risk of asthma severityhad a positive 
association with medication adherence rates (p<0.05). Finally, patients with prior 
outpatient visits were positively associated with medication adherence of 80% (p<0.01).   
[Table 5.4 goes about here] 
 Table 5.5 shows the results of logistic regression measuring the association 
between type of Medicaid payment mechanisms and likelihood of health care utilization. 
In this case, the dependent variables were the likelihood of health care utilization (office 
visit, hospitalization, and ER visit). Regarding with likelihood of office visit, patients on 
capitated plans were 26% less likely to visit outpatient clinics as compared to those with 
FFS (p<0.01). Female children were 100% more likely to visit outpatient clinics as 
compared to male children. African American and Hispanic children were less likely to 
visit outpatient clinics than white patients (44% and 11% respectively, p<0.05). Patients 
with higher medication possession rates were 31% less likely to visit to the outpatient 
clinics. Patients with more risk of asthma severitywere 92% more likely to visit the 
outpatient clinic than those with no conditions (p<0.01). There were no significant effects 
of total number of prescriptions, prior number of outpatient visits and total expenditure 
on the number of office visits. 
 We also performed poisson regressions to find the association between type of 
Medicaid payment mechanisms and the number of outpatient visits. Table 5.5 shows that 
patients in capitated health plans had 52% lower number of outpatient visits compared 
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with those on FFS (p<0.05). Female patients had 18% higher number of outpatient visits 
compared with male patients (p<0.05).  African American and Hispanic patients (18% 
and 31% respectively, p<0.01) were less likely to visit the outpatient clinic than White 
patients.    
 When predictors of hospitalizations were examined, patients in capitated health 
plans had 34% more likelihood of hospitalizations when compared to those in FFS 
(p<0.01). Hispanic children were 43% more likely to get hospitalized than White 
(p<0.01) children with asthma. Patients who had a higher medication possession rates 
were 18% less likely to have a hospitalization (p<0.05).  The patients who had a prior 
outpatient visit were 19% less likely to get hospitalized than those who had not (p<0.05).  
Examining frequency of hospitalizations, patients enrolled in capitated plans were 
52% higher frequency of being hospitalized as compared to those with FFS. Hispanic 
children had 9% more frequently hospitalized compared to White (p<0.05) children with 
asthma. Patients who had a higher controller asthma drug ratio (the ratio of controller 
medication to total medications >0.5) were 41% less frequently hospitalized compared to 
those who did not (p<0.01). Patients who had a higher medication possession rates were 
44% less frequently hospitalized (p<0.01). There were no significant effects of prior 
number of outpatient visits and total expenditures on the number of hospitalizations.  
 Results of logistic regression  (Table 5.5) showed that asthmatic children enrolled 
in capitated health plans had 25% increased likelihood of having an emergency room 
visit when compared to those in FFS (p<0.01).  Children who were in the age group 5-18 
years were 61% less likely to have an emergency room visit when compared to those 
aged between 1-4 years (p<0.01). African American and Hispanic children with asthma 
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were (7% and 16% respectively, p<0.01) more likely to visit the ER department than 
White children. Children with asthma who took more controller medication were 61% 
less likely to visit the ER department than those who took more reliever medications 
(p<0.01).  Children with prior either event of hospitalization or event of ER visit were 
79% more likely to have ER visits in follow up period (p<0.01). Increase in one total 
number of prescriptions was associated with 61% increase in likelihood of emergency 
room visit (p<0.01).      
Patients with capitated plans had 32% more frequently to have ER visits 
compared in FFS plan (p<0.01). African American and Hispanics had more (23% and 
19%, respectively) frequent ER visits compared with White (p<0.01) children. Patients 
who had higher controller use (the ratio of controller medication to total medications 
>0.5) had 52% less frequent ER visits (p<0.01). Children with more risk of asthma 
severitywere more (7% and 57%, respectively) frequently seen in ERs (p<0.01). 
However,  patients who had prior outpatient visits were 53% less frequent ER visits 
(p<0.01).  There was no significant effect of total expenditure on the number of ER visits. 
[Table 5.5 goes about here] 
 
Discussion 
There was a significant difference in anti-asthmatic medication adherence across 
different health plans. The cutoff for the medication possession rate (MPR) was 80%. At 
quantile of 80% MPR, compared to FFS plans, captitated plan enrollees had significantly 
lower medication adherence. Captitated plans provide fixed dollar amount per member 
per month for all pharmaceutical services which limits the prescription drug benefits for 
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captitated plan enrollees. These plans have caps where the plan enrollees get some 
benefits on the basis of a predictable level of total expenditure in a market where 
medication costs are increasing rapidly. Once the limit is reached, the plan enrollees have 
to bear out of pocket expenses for covering their pharmaceutical care. Also, patients 
enrolled in capitated plans were more likely to have hospitalizations and ER visits 
compared to FFS plan. Some of the negative aspects associated with enrolling in 
capitated plans are under-treatment, substitution due to inadequate health service 
coverage, cost shifting to other services, and poor treatment provision. Our study also 
showed that children enrolled in capitated plans had lower medication adherence 
compared to children enrolled in FFS plans which indicates that poor healthcare 
outcomes and excessive healthcare utilization might be associated with capitated plans.  
Even though capitated plans have some negative aspects, they motivate providers 
and health plans by providing direct financial incentives to manage utilization. On the 
other hand, this might lead to limited patient follow-up or shorter treatment duration. This 
could also drive lower medication adherence in captitated patients. Higher medication 
adherence is associated with lower hospitalizations and ED visits in asthma patients. So, 
it is important to maintain medication adherence in pediatric asthma patients. 
 There are several limitations for this study. First, the states from which the 
Medicaid sample was drawn were not individually identified due to patient privacy 
reasons. Thus, we could not explore how eligibility requirements could vary study 
outcomes across the states. Second, like most studies that use claims data, specific 
clinical information that is only available from patient chart review or electronic medical 
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records was not obtainable. As such, data concerning physician adherence to guidelines 
was incomplete, and patients’ severity of asthma and health beliefs were not included. So, 
asthma severity scores in the pre-index period were used as a proxy for patient risk. 
Finally, administrative data can also suffer from data entry errors or omissions that can be 
difficult to detect or evaluate.  
 Despite limitations of this study, further research is needed to understand the 
reasons for the higher health care utilization but lower medication adherence for capitated 
plan enrolled children with asthma compared to similarly placed children in FFS plans. In 
particular, it is important to decide whether lower medication adherence for capitated 
plan-enrolled asthmatic children influences higher health care utilization (hospitalizations 
and ER visits) for the same services provided in the long run. Lower medication 
adherence could have potentially adverse outcomes related to health care utilization. 
Alternatively, fixed payments could reflect less intensive or lower quality services 
provided to capitated plan enrolled children with asthma. Further research is needed to 
assess the type of quality of care delivered to children with asthma and its relation to 
health outcomes in capitated plan- enrolled children with asthma. 
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Table 5.3 Patient characteristics across the Health Plans 
 
Variables Measure Capitation (n=2607) N (%) / mean (SD) 
FFS (n=3828) 
N(%)/ mean (SD) P-value 
Age in years 
Sex 
 
Race/ethnicity 
 
 
Visit to pediatrician 
Hospitalization 
ER visit 
Medication Possession Ratio 
MPR 
           <40% 
           <80% 
>80% 
Asthma drug ratio > 0.5 
Severity Index  
            1 
            2 
            3 
Total number of prescriptions 
Number of outpatient visits  
Continuous 
Male 
Female 
White 
Black 
Hispanic 
(yes/no) 
(yes/no) 
(yes/no) 
Continuous 
Categorical 
 
 
 
(yes/no) 
Categorical 
 
 
 
Continuous 
count 
7.5 (6.4) 
980 (37.5%) 
1627 (62.5%) 
1320 (50.6%) 
1132 (43.4%) 
155 (6.0%) 
1980 (75.9%) 
960 (36.8%) 
1982 (76.0%) 
34.72 (29.53) 
 
1987 (76.2%) 
459 (17.6%) 
161 (6.2%) 
1182 (45.3%) 
 
860 (32.9%) 
884 (33.9%) 
863 (33.2%) 
22.3 (19.3) 
7.2 (11.2) 
8.7 (7.1) 
1489 (38.8%) 
2339 (61.2%) 
1872 (48.9%) 
1698 (44.3%) 
258 (6.7%) 
2976 (77.7%) 
1172 (30.6%) 
1779 (46.4%) 
45.49 (41.11) 
 
2234 (58.3%) 
689 (18%) 
905 (23.7%) 
2367 (61.8%) 
 
1362 (35.6%) 
1287 (33.4%) 
1179 (31.0%) 
29.4 (26.4) 
10.7 (14.6) 
<0.01 
<0.01 
 
<0.01 
 
 
<0.01 
0.187 
<0.05 
<0.01 
<0.05 
 
 
 
<0.01 
<0.01 
 
 
 
<0.01 
<0.01 
*: p<0.05 **: p<0.01 
Severity index: 
1: No events,  
2: 15 or more beta- Agonist canisters or 1 or more filled prescriptions for oral corticosteroids,  
3: Hospitalization or Emergency Department encounters 
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Table 5.4 Comparison of Predictors of Medication Adherence Rates across Health 
Plans using Quantile Regression. 
  MPR – 40 % (quantile)  MPR – 80% (quantile) 
Variables B (SE) 95% CI B(SE) 95% CI 
Type of health plan    
  FFS 
 Capitated 
Age group: 
1-4 
5-18 
Sex 
Male                              
Female                          
Race/ethnicity 
  White 
  Black 
  Hispanic 
Visit to pediatrician 
Asthma drug ratio  > 0.50 
Severity Index  
   1  
 2 
   3 
Total number of 
prescriptions 
Number of outpatient 
visits  
Total Expenditure 
Constant 
 
Ref 
0.08 (0.52) 
 
Ref 
2.01 (0.53) 
 
Ref 
-0.84 (0.43)* 
 
Ref 
-1.21 (0.44)** 
-1.81 (0.98)* 
6.75 (1.04)** 
-13.08 (1.45)** 
 
Ref 
-1.99 (1.36) 
-1.55 (1.41) 
0.18 (0.28) 
 
-0.03 (0.06) 
 
0.18 (0.01)** 
21.97 (2.80) 
 
 
(-0.93, 1.10) 
 
 
(0.97, 3.03) 
 
 
(-1.68, -0.01) 
 
 
(-2.08, -0.34) 
(-3.74, 0.13) 
(4.71, 8.79) 
(-15.92, -10.24) 
 
 
(-4.66, 0.66) 
(-4.31, 1.27) 
(-0.38, 0.72) 
 
(-0.22, 0.03) 
 
(0.15, 0.19) 
(16.48, 27.46) 
 
Ref 
-1.14(0.58)** 
 
Ref 
2.35 (0.72)** 
 
Ref 
-0.02(0.44) 
 
Ref 
-0.23 (1.57) 
-0.88 (0.37)* 
7.71(0.87)** 
27.74 (1.43)** 
 
Ref 
0.06 (0.01)** 
0.09 (0.04)* 
0.19 (0.04)* 
 
0.02 (0.002)** 
 
0.15 (0.04)** 
41.64(3.44) 
 
 
(-2.28, -0.01) 
 
 
(0.94, 3.77) 
 
 
(-0.88, 0.84) 
 
 
(-3.32, 2.85) 
(-1.89, -0.11) 
(6.00, 9.42) 
(24.92, 30.56) 
 
 
(0.05, 2.07) 
(0.01. 3.18) 
(0.11, 1.26) 
 
(0.01, 2.03) 
 
(0.06, 1.24) 
(34.88, 48.41) 
*: p<0.05 **: p<0.01 
Severity index: 
1: No events,  
2: 15 or more beta- Agonist canisters or 1 or more filled prescriptions for oral corticosteroids,  
3: Hospitalization or Emergency Department encounters 
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Table 5.5 Comparison of Health Care Utilization across Health Plans using Logistic 
and Poisson Regressions 
OR 95% CI IRR 95% CI OR 95% CI IRR 95% CI OR 95% CI IRR 95% CI
Ref Ref Ref Ref Ref Ref
0.74* (0.59, 0.98) 0.48* (0.28, 0.67) 1.34** (1.07, 1.59) 1.52** (1.16, 1.89) 1.25** (1.03, 1.57) 1.32** (1.22, 1.46)
1-4 Ref Ref Ref Ref Ref Ref
5-18 0.79 (0.61, 1.03) 0.89 (0.72, 1.04) 1.29 (0.71, 2.33) 1.16 (0.91, 1.52) 0.39** (0.13, 0.67) 0.78 (0.52, 1.15)
Male Ref Ref Ref Ref Ref Ref
Female 2.14** (1.69, 2.87) 1.18* (1.07, 1.31) 0.84 (0.65, 1.09) 0.93 (0.76, 1.18) 0.84 (0.53, 1.39) 0.96 (0.73, 1.26)
White Ref Ref Ref Ref Ref Ref
Black 0.56* (0.27, 0.89) 0.82** (0.70, 0.89) 0.79 (0.54, 1.07) 0.94 (0.75, 1.23) 1.07** (1.02, 1.35) 1.23** (1.10, 1.37)
Hispanic 0.89* (0.62, 0.97) 0.69** (0.44, 0.87) 1.43** (1.02, 1.98) 1.09* (1.07, 1.11) 1.16** (1.04, 1.47) 1.19** (1.04, 1.39)
1.27 (0.73, 2.22) 1.06 (0.88, 1.21) 0.76* (0.62, 0.98) 0.88 (0.56, 1.37) 1.01 (0.91, 1.23) 0.91 (0.54, 1.53)
1.11 (0.74, 1.76) 1.01 (0.99, 1.02) 0.23** (0.04, 0.42) 0.59** (0.42, 0.72) 0.39** (0.24, 0.59) 0.48** (0.40, 0.54)
0.69* (0.27, 0.99) 0.34** (0.24, 0.45) 0.82* (0.71, 0.99) 0.56** (0.46, 0.69) 0.64** (0.48, 0.75) 0.58** (0.45, 0.73)
1 Ref Ref Ref Ref Ref Ref
2 1.92** (1.43, 2.49) 1.23** (1.07, 1.38) 1.46** (1.08, 1.89) 1.12 (0.79, 1.54) 1.24** (1.06, 1.53) 1.07** (1.02, 1.09)
3 1.27 (0.89, 1.75) 1.19** (1.06, 1.31) 1.39** (1.03, 1.76) 1.58** (1.12, 2.64) 1.79** (1.42, 2.31) 1.57** (1.14, 2.34)
1.05 (0.65, 1.46) 1.02 (0.89, 1.16) 1.42** (1.18, 1.74) 1.06** (1.02, 1.12) 1.61** (1.29, 1.97) 1.11** (1.04, 1.18)
1.01 (0.79, 1.37) 1.36 (0.72, 2.43) 0.81* (0.66, 0.98) 1.10 (0.88, 1.44) 0.57** (0.32, 0.86) 0.47** (0.38, 0.57)
0.91 (0.64, 1.28) 0.99 (0.91, 1.08) 0.84 (0.63, 1.04) 0.91 (0.74, 1.13) 0.61 (0.21, 1.83) 0.76 (0.48, 1.19)
Severity Index
Total # of Prescriptions
# of Outpatient visits
Total Expenditure
Variables
Age group
Sex
Race/Ethnicity
Visit to Ped. Doctor
Asthma drug ratio > 0.5
MPR 
       Office visit Hospitalization ER visits
FFS
Capitated
Type of health plan
 
*: p<0.05 **: p<0.01 
Severity index: 
1: No events,  
2: 15 or more beta- Agonist canisters or 1 or more filled prescriptions for oral corticosteroids,  
   3: Hospitalization or Emergency Department encounters 
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3 ER 6 
CHAPTER 6 
DISSERTATION MANUSCRIPT #3: COMPARISONS OF HEALTHCARE 
UTILIZATION OUTCOMES IN COMMERCIAL VERSUS MEDICAID-
ENROLLED ASTHMATIC CHILDREN 
 
     ABSTRACT 
The purpose of this retrospective cohort study was to examine the impact of the type of 
health plan (public insurance vs. private insurance) on outcomes (health care utilization 
and medication adherence) in pediatric asthmatic enrollees. Subjects were 11,027 
asthmatic children (6,435 enrolled in Medicaid and 4,592 enrolled in a commercial 
HMO) who newly started asthma pharmacotherapy and were followed 12 months before 
after the index anti-asthmatic medication fill.  Data on health care utilization and 
medication adherence were examined to compare health care utilization-based outcomes. 
Quantile regression analysis was used to examine predictors of medication adherence 
while logistic and poisson regressions were used to examine health care utilization 
predictors. Patients in private insurance plan had significantly higher medication 
adherence rates. (p<0.01) compared to those in Medicaid plans. Patients in Medicaid 
plans were also associated with 20% more inpatient hospitalizations and 50% increased 
odds of emergency department visits, but had 42% fewer outpatient visits compared to 
those in private plan (all p<0.05). Although children with asthma enrolled in Medicaid 
receive fairly comprehensive coverage of medical services, further research is needed to 
determine the reasons for poor healthcare utilization related outcomes in this population. 
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Introduction 
 
Asthma is a chronic respiratory disease characterized by episodes or attacks of 
inflammation and narrowing of small airways in respiratory system. Asthma attacks can 
vary from mild to life-threatening and may involve shortness of breath, coughing, 
wheezing, chest pains or tightness, or a combination of these symptoms. Many factors 
like allergens, infections, exercise, abrupt changes in the weather, or exposure to airway 
irritants, such as a tobacco smoke can trigger an asthma attack (NCHS, 2005). 
Some of the most established measures of prevalence of asthma are the Center for 
Diseases Control’s (CDC) Behavioral Risk Factor Surveillance Survey (BRFSS) and the 
National Health Interview Survey (NHIS) (CDC 2007; NCHS 2005). These surveys have 
the usual limitations associated with self-reported data like non-response bias, and low 
precision for state and sub-state estimates associated with surveys that used multistage 
sample selection with the goal of developing national estimates. Additionally, the BRFSS 
only surveys adults, and the NHIS had a relatively small sample of children that 
precludes state level estimation. A change in NHIS questionnaire language in 1997 
concerning asthma prevalence made comparisons to periods before and after that date 
problematic. Given these limitations, estimates of the lifetime prevalence of asthma 
among adults had ranged from 10-12% over the past 6 years while current asthma for 
adults is generally reported at approximately 7-8% (Mannino 2002). National estimates 
suggested that lifetime asthma prevalence for children less than 18 was approximately 
12.5% with age specific prevalence of 7.5, 14, and 14.7 percent for children aged 0-4, 5-
11, and 12-17 respectively (CDC 2005). 
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Poor and minority children bear a disproportionate share of the population burden 
of asthma. This is reflected in higher rates of hospitalization and emergency room visits 
for asthma, lower utilization of pharmaceutical agents known to improve control of 
asthma, higher prevalence and severity of the disease, lower rates of utilization of 
primary care services related to asthma (Akinbami and Schoendorf 2002; Ash 2005; 
Dougherty 2005; Gold and Wright 2005; Krishnan 2001; Lieu et al. 2002; Weiss, 
Sullivan, and Lyttle 2000). This is likely due to characteristics of the U.S. medical care 
system (especially financing), and its concomitant impact on access to medical care 
(Bindman 1995; Friedman 2001; Homer 1996) and to individual characteristics of the 
population (Lynch 1997). Poor children are more vulnerable to poor health in general 
because they are apt to have multiple risk factors (Aday 2001; Chang et al. 2011). 
Investigation of single risk factors is useful but is perhaps does not reflect the real-world 
scenarios where risk factors often cluster, e.g., low education and low income (Stevens et 
al. 2006). Previous research has suggested that multiple risk factors may produce an 
additive impact on children's mental, physical, and social health and school performance 
(Starfield, Robertson, and Riley 2002; Stevens et al. 2006) and with asthma health in 
particular (Wood 2002). This study examined the differential impact of managed care 
services on healthcare utilization, access to care and quality of pharmaceutical care and 
associated outcomes in both Medicaid (poorer) and privately insured (richer)pediatric 
populations with asthma. 
One of the key components for long-term control of asthma is pharmacotherapy, 
and previous studies confirm that the daily use of steroid inhalant would greatly reduce 
asthma symptoms, occurrence of severe exacerbations, use of quick-relief medications, 
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and lung function measured by peak flow, FEV and airway hyper responsiveness 
(Cloutier et al. 2005; Cochrane 1999). Several factors affect patient adherence to 
medications. Insurance coverage/type of health plan plays a key role in providing access 
to essential health care services. With no or limited insurance coverage, patients who use 
more drugs face increasing out-of-pocket costs, which may result in decreased adherence 
(Janson and Weiss 2004). The access to pharmaceutical innovation is also mediated by 
the patient’s primary source of health insurance coverage. Patients with public insurance 
(Medicare and Medicaid) are less likely to receive newer medications for the 
management of chronic diseases (Cloutier et al. 2005). Managed care organizations 
provide services to both types of populations in order to improve asthma quality of care 
and healthcare utilization through provision of a) equal access to care using shared 
provider networks, b) case management using patient support and c) shared management 
expertise for all plans. The plan characteristics and services provided in both the 
programs might share dissimilarities with regards to certain services like patient cost 
sharing or transportation assistance. 
The managed care brought about a revolution in the US healthcare system in the 
1990s by significantly bringing down the healthcare spending throughout the nation. 
During the recent years, people had been unhappy about some of the restrictive policies 
of managed care and had shown preference for the less restrictive Preferred Provider 
Organizations (PPOs). PPOs have managed cost controls using their negotiation power 
with regards to reimbursement rates. The evidence quality of care provided by MCOs 
showed inconclusive results and the evidence about quality of care provided by other 
plans is absent. Evidence of gaining long term financial incentives through delivery of 
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evidence based quality health care and promotion of preventive care by MCOs over 
gaining short term incentives through restricting utilization lacks sufficient evidence 
(Miller and Luft 1993; Miller and Luft 1994a, 1994b; Miller and Luft 1997, 2002). 
Previous studies have examined health services utilization and expenditures in children 
with asthma by individual states or individual health plans (Draper, Hurley, and Short 
2004; Twiggs et al. 2002; Wagner 2005). These studies had smaller sample sizes (Lapolla 
et al. 2004) and looked at study periods when patients had hospital stays (Ash 2005; 
Bodenheimer 2002). 
The purpose of our study was to compare prevalence and estimates of health care 
utilization and expenditures associated with asthma in children aged 1–18 years across 
those enrolled in commercial (HMO) plans and those enrolled in public (Medicaid) plans 
to determine potential differences in quality and access to asthma heath care in inpatient 
or outpatient settings.  
 
Materials and Methods 
This study used the MarketScan® Medicaid/Commercial claims dataset licensed 
from Thomson Medstat for the period 2005-2007. In 2007, the Medicaid database 
included claims for approximately 5.4 million pediatric enrollees in eight unidentified 
states, and the Commercial database included claims for 15.5 million enrollees from 100 
payers across the U.S. We refer to children in the commercial database as privately 
insured. The states were de-identified. However, the data consisted of at least one state 
from each U.S. region. The database consisted of medical (outpatient and inpatient 
services), drug, and long-term care claims and eligibility records for enrollees from these 
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states. The prescription drug coverage was provided by all the states. The data were 
available from 2005 to 2007 representing around 5.4 million individuals in the United 
States (MarketScan® research database, 2008). For the purpose of this study, the research 
database were updated and queried from January 1, 2005 to December 31, 2007. The 
database was HIPPA compliant and features encrypted member and service provider 
identification numbers. The data from these states provided a fairly large sample of the 
enrollees in the U.S. The dataset also provided additional information on variables such 
as race/ethnicity, Medicare eligibility and Medicaid eligibility / federal aid category.  
The study population comprised of children aged 0 to 18 years of age. The 
patients with a diagnosis of asthma and a prescription of a new asthma medication 
(Inhaled Bronchodilator, Anti-Inflammatory, Systematic Bronchodilator, Systematic 
Corticosteroid and/or Leukotriene Modifiers) during the study time period included. 
Subjects with a primary or secondary diagnosis of asthma identified using the 
International Classification of Diseases Code 9th Revision (ICD-9: 493.XX) obtained 
from the inpatient claims during the study test period. Only subjects who have maintained 
continuous eligibility for 1 year period between January 1, 2005 and December 31, 2005 
included in the study. The date for the first prescription claim for anti-asthmatic 
medication use designated as an index date, where the medication identified using 
relevant National Drug Codes (NDC) recorded in the claim records. The study required 
all patients to have continuous health plan enrollment for at least 1 year prior to and 
following their index date by insuring that each patient’s index date presents a reasonable 
marker for treatment initiation as well as making sure that any observed lack of health 
care events was due to a lack of medical activity and not due to cessation of insurance. 
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The identification period ranged from January 1, 2006 to December 31, 2007. During this 
time period, any patients who have an asthma diagnosis and who were prescribed an anti-
asthmatic medication were included. 
 
Measurement and Outcomes 
The operational definitions and measurements of the variables utilized in this 
study discussed in this section. The dependent variables for this study are medication 
adherence, hospitalizations, outpatient visits, and emergency room (ER) visits. The main 
independent variable tested in this study is the type of health plan (public vs. private). 
Other independent covariates include age, gender, access to specialty care, and disease 
severity. The operational definition of each variable described in the following sections: 
 
Medication adherence 
Medication adherence signified medication usage by patients. It was basically the 
act of conforming to the physician’s recommendations about the timing, dosage, and 
frequency of medication intake.  The International Society of Pharmacoeconomics and 
Outcomes research defined medication adherence as the extent to which a patient 
complies with the intended dosing regimen (Hess 2006). The unit of measure for 
compliance was administered doses per defined period of time, reported as a proportion 
(%) of prescribed doses (D) taken at the prescribed time interval (T) as measured by the 
period of time.  
  Medication adherence can be measured directly and indirectly by utilizing 
biological markers, blood and urine assays, patient interviews, pill counts, prescription 
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refills, and electronic monitoring (Claxton, Cramer, and Pierce 2001; Hess 2006). Since 
the study uses insurance claims database, prescription refill patterns can be used to 
capture medication adherence. The information thus obtained records the frequency and 
timeliness of refills of prescribed medication and eliminates any Hawthorne effect. Also 
pharmacy records had predictive validity as measures of cumulative exposure and gaps in 
medication supply (Steiner 1998). On the other hand the method also had some 
limitations like presence of data on unusual refill patterns, multiple conflicting drugs and 
inability to capture all data about patients visiting multiple pharmacies. Also utilization of 
pharmacy records assumed that “a prescription filled is a prescription taken” 
(Balkrishnan 2005). The data cannot measure actual consumption but only estimates 
about actual medication consumption (Hess 2006). 
Medication adherence in this study indicates patient’s intake of oral anti-asthmatic 
prescription medication. Data from the pharmacy claims database can be used to measure 
medication adherence by several ways. Medication possession ratio (MPR) is one such 
measure used to calculate medication adherence. For the purposes of this study, MPR is 
calculated as the days of anti-asthmatic medication supply dispensed divided by the 
number of days in the observation period (#365) minus the number of days in the hospital 
(Camargo 2007; Hess 2006; Sokol et al. 2005). Thus, MPR for this study is defined as  
MPR= # of days supply of anti-asthmatic medication in the post-index period / # of days 
in the study period (365 days).  
 
The observation period in this study included the post-index period or 12 month 
follow up period which was consistent for each patient. The number of hospital days was 
subtracted from the denominator because any drug taken during this period was given to 
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the patient by the hospital and was not possible to capture in the pharmacy records. The 
information on each filled prescription included of dispensing, quantity dispensed, and 
days supply of medication. We were placed into 2 categories: asthma controller 
medications and reliever medications. Controller medication consisted of ICSs, 
ICSs/LABAs, LABAs, LTRAs and theophylline. Reliever medication included short-
acting β-agonists (SABAs) and systemic corticosteroids. We examined the distribution of 
the day of supply for the medications, summing for each patient the number of days 
supplied by their prescriptions for the 365 days of follow-up. The MPR was calculated 
for asthma medication possession on a given day of the year and avoided double counting 
of multiple asthma medication use on the same day by the same patient.  
 
Healthcare Service Utilization 
Patients were followed during pre-index and post-index period (i.e. 12 month 
before and 12 months after the index date) to assess their healthcare utilization in terms 
of hospitalizations, ER visits, outpatient visits. The variables hospitalizations, ER visits 
and outpatient visits are used as a proxy for health care service utilization. To identify 
hospitalization event in patients, their admission and discharge dates recorded in inpatient 
service files are used. CPT codes as well as service codes were taken from the inpatient 
and outpatient services files for identifying events of ER visit and outpatient visits. 
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Sociodemographic variables 
The following sociodemographic variables were taken from the Medicaid data: 
gender, birth year and race/ethnicity. Birth year of the patients is used to calculate their 
age. Race or ethnicity of patients is classified as whites, blacks, Hispanics and others.  
 
Proxy for asthma severity 
 
Based on the established relation between disease severity and intensity of 
treatment, severity of a condition in the current period is inferred by a risk of an 
exacerbation in a future. Some of the independent predictors widely used in the literature 
for ascertaining future asthma-related emergency hospital utilization (EHU) are 
hospitalizations, use of emergency department and use of oral corticosteroids (Roth 2004; 
Schatz 2004). Severity of asthma in the current period was assessed by determining high 
risk of EHU.  A popular type of risk stratification scheme used is a simple three-level risk 
stratification which ranks risk of future EHU based on a point system applied to a period 
portraying current utilization. Points are assigned to different indicators of future asthma 
related EHU. Asthma hospitalizations or ED encounters in the 12-month base period are 
assigned 2 points, 15 or more beta-agonist canisters in the base period are assigned 1 
point and 1 or more filled prescriptions for oral corticosteroids are assigned 1 point. 
Members are differentiated on the basis of assignment of points. Members with 2 or more 
points, 1 point and 0 point are classified as high risk, medium risk and low risk groups 
respectively (Schatz 2004). This has been summarized in the following Table 6.1. 
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Table 6.1 Three-Level Risk Stratification of Asthma Severity 
 
Event per 12-
month base 
period 
Potential Point 
Assignment 
Low Risk 
0 Points 
Medium Risk 
1 Points 
High Risk 
2 or more 
Points 
A. ED visits 
asthma 
encounter 
2 0 0 2 
B.  IP visits 
asthma 
encounter 
2 0 0 2 
C. 15 or more 
beta-agonist 
canisters 
dispensed 
1 0 1 1 
D. Any oral 
corticosteroid 
prescriptions 
dispensed 
1 0 1 1 
Required events 
for risk level 
 No listed 
events 
Either C or D Either A or B 
and/or C and D
Therefore, the measurement of asthma severity is the probability of an asthmatic member 
having a risk score (severity proxy) of 0,1, or 2. 
 
Table 6.2 Analytical Framework and Study Covariates for Chapter 6 
 
Target population: Children aged 0 to 18 years with a diagnosis of asthma receiving  
                                 care in a Medicaid Setting and Commercial plan 
Outcomes: Medication Possession Rate, Healthcare services utilization (ER, IP & OP),  
Regressor of interest: Health plan (Public vs. Private)  
Covariates: 
Patient Characteristics: Patient’s age, gender, and race/ethnicity (Predisposing factors) 
Patient’s Medical Conditions: Asthma severity                              (Need factors) 
Physician Characteristics: Specialty                                              (Enabling factors)  
Asthma Drug Ratio: A controller to total asthma medication ratio of 0.5 or more 
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Statistical Analysis 
Descriptive statistics were performed to compare baseline characteristics. 
Continuous data were described by means and standard deviations, and nominal and 
categorical data were described by frequencies and percentages. Unadjusted 
demographic, clinical, and medication characteristic comparisons between groups were 
completed using independent sample t tests for evaluation of continuous variables and 
chi-square tests for categorical variables. The data were analyzed using STATA software 
version 10 (Stata Corp, College Station, TX). All univariate, bivariate, and multivariate 
analyses were conducted at a set a priori level of significance (0.05). 
Quantile regression was used to evaluate the relationship between the type of 
health plan and medication adherence after controlling for potential covariates. Quantile 
regression provides a convenient linear framework for examining how the quantiles of a 
dependent variable change in response to a set of independent variables, allowing the 
estimation of linear conditional quantile functions.  The primary independent variable 
was the type of health plan (public vs. private). Other covariates included in the model 
were demographic (age, sex, rac/ethnicity), clinical variables such as severity index 
including health care resource utilization in pre-index period (hospitalizations, ER visits), 
and therapy-related variables (appropriate medication choice). 
The normality was determined using the Shapiro–Wilk test. The 
heteroskedasticity was determined using the White test. The data were also examined for 
multicollinearity (ie, a linear relationship between predictor variables). A variation 
inflation factor of <10 was considered to indicate absence of multicollinearity. 
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Logistic regression model was used to predict the likelihood of healthcare 
utilization (outpatient, inpatient, and ER visit). Additionally, the poisson regression 
model was used to predict the frequency of healthcare utilization (outpatient, inpatient, 
and ER visit) while the zero-inflated poisson regression model was used to predict the 
number of hospitalizations. The adequacy of model was examined using the Vuong test. 
 The following were the description of the models for this study. Before we 
examined the main outcomes, we tested for differences across groups by Chow test. The 
Chow test examines whether a regression function is different for one group (Medicaid) 
versus another (Private); it can be thought of as simply testing for the joint significance of 
the dummy and its interactions with all other covariates, thus providing evidence that we 
can merge two data sources (in this case, two sets of claims data). After pooling data with 
Medicaid and private insurance, we computed the proper F statistic without running the 
unrestricted model with interactions with all k continuous variables. The results of this 
test indicated that the data could be pooled for analysis (F= 46.14, p<0.000).  
We then examined predictors of medication adherence using the quantile 
regression and the following model: 
MPR (anti-asthmatic medication adherence-quantile regression) 
= ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (Medicaid vs. Commercial) + e 
Where MPR stands for the medication possession ratio to measure anti-asthmatic 
medication adherence, and e is the error term. 
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 We then examined the likelihood and frequency of health care service utilization 
using a series of logistic and poisson regression models which can be delineated as 
follows: 
Pr [Y [health care utilization] = 0 or 1] 
= f [ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (MPR) + ß6 (Medicaid vs. Commercial)] + e 
where Y = 1 if some specific health care is utilized and Y = 0 if not; f(•) is the cumulative 
density function (CDF) of logistic distribution and e is the error term. 
Asthma-related healthcare utilization (a count variable, the number of visits) 
= ß0+ ß1 (patient predisposing factors) + ß2 (patient enabling factors) 
+ ß3 (patient need factors) + ß4 (type of anti-asthmatic medication) 
+ ß5 (MPR) + ß6 (Medicaid vs. Commercial) + e 
 
Results 
 The study cohort consisted of a total 11,027 children with asthma. The 
characteristics of this cohort with a mean age 8.2 years (standard deviation [SD]: 6.9) are 
shown in Table 6.3. A total of 6,435 children were enrolled in Medicaid and 4,592 
children were enrolled in private insurance, reflecting the lower prevalence of children in 
the commercial claims data. Among the population captured in the commercial claims 
dataset, Medicaid enrollees were slightly more likely than privately insured children to 
have had a hospitalization in 2007, 33.1% vs. 28.7% (p<0.05).  When compared to 
Medicaid patients, children enrolled in private insurance had a significantly higher MPR 
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value (40.11 vs. 45.74; p<0.01). Medicaid enrollees were more likely than privately 
insured children to have had an ER visit in 2007, 58.4% vs. 32.6% (p<0.01). Also, 77.0% 
of Medicaid and 83.9% of privately insurance enrollees had at least one pediatrician visit 
(p<0.01). The mean number of outpatient visits was 8.9 for Medicaid and 11.5 for private 
insurance enrollees (p<0.01). The total number of asthma medications prescribed were 
more in Medicaid enrollees compared to private insurance enrollees, 25.9 vs. 12.8 
(p<0.01). Mean total expenditure were $11,075 for Medicaid and $14,722 for private 
insurance enrollees with asthma; that is, 25% lower for Medicaid.    
[Table 6.3 goes about here] 
 Table 6.4 showed the comparison of predictors of medication adherence rates to 
asthmatic medication in asthmatic children across the health plans (public vs. private). 
We examined predictors using two cutoff rates of medication possession (40% vs. 80%). 
In this case of quantile 40% of medication adherence, there were several factors 
associated with medication adherence. First, female children were positively associated 
with medication adherence of 40% (1.13, p<0.01). Second, the patients aged 5-18 years 
had a positive association with low medication adherence (0.36, p<0.05) as well 
compared to the very young children. Third, Hispanic children had a slightly positive 
association with low medication adherence (0.13, p<0.05). Fourth, total expenditure is a 
little positively associated with low medication adherence (0.03, p<0.01). There were no 
significant differences in adherence between severity index, total number of prescription 
and number of outpatient visits.  
 We also examined the effect of the type of health plan (public vs. private) on 
higher medication adherence rates (quantile 80%). There were again several factors that 
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were associated with higher medication adherence. First, children with private insurance 
plan had strong positively associations with higher medication adherence (β=4.79, 
p<0.01). Second, children aged 5-18 years had positively associated with higher 
medication adherence (β=4.94, p<0.01). Third, patients who saw pediatricians were 
significantly positively associated with higher medication adherence (β=6.51, p<0.01). 
Fourth, asthma controller ratio > 0.5 (ratio of controller medication to total medication) 
was positively associated with higher medication adherence (β=1.08, p<0.01). Fifth, 
children with more risk of asthma severitywere positively associated with higher 
medication adherence (β=0.07, p<0.01). Finally, children with prior outpatient visits were 
positively associated with higher medication adherence (β=0.02, p<0.05).  
[Table 6.4 goes about here] 
 Table 6.5 shows the results of logistic regression measuring the association 
between type of insurance and likelihood of health care service utilization. In this case, 
the dependent variables were the likelihood of health care utilization (office visit, 
hospitalization, and ER visit). When likelihood of office visit was examined, patients 
with private insurance plans were 23% more likely to visit the outpatient clinics as 
compared to those with public insurance (p<0.01). Female children were 32% more likely 
to visit the outpatient clinic as compared to male children. African American and 
Hispanic children were (46% and 38% respectively, p<0.05) less likely to visit the 
outpatient clinic than White children. There were no significant effects of total number of 
prescriptions, prior number of outpatient visits and total expenditure on the number of 
office visits. From the results of poisson regressions (Table 6.5), examining the number 
of office visits, there was evidence of higher frequency of office visits among private 
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children (1.42, p<0.01) and as expected increased frequency of office visit with 
increasing age group (1.29, p<0.01). Unsurprisingly, African American and Hispanic 
children had lower (37% and 24%, respectively) frequencies of office visits (p<0.05). 
 When hospitalizations were examined, patients with private insurance plans had 
68% lower likelihood of hospitalization when compared to those with public insurance 
(p<0.01). African American and Hispanic children were (82% and 22% respectively, 
p<0.01) more likely to get hospitalized compared to White children (p<0.01). Patients 
who had higher medication possession rates were 41% less likely to have a 
hospitalization (p<0.05).  Patients who had a prior outpatient visit were 38% less likely to 
get hospitalized than those who did not have one (p<0.05).  Next when we examined 
hospitalization frequency, children with private insurance plan were 20% less likely to be 
getting hospitalized as compared to those with public insurance plan. Hispanic children 
were 52% more likely to have a hospitalization compared with White (p<0.05). Patients 
who had a good medication adherence rates were 18% less likely to have a 
hospitalization (0.82, p<0.01). As expected, higher asthma severity was associated with 
higher likelihood of the hospitalization (1.41, p<0.05). There were no significant effect of 
total expenditure, total number of prescription, and asthma drug ratio on the number of 
hospitalizations. 
 When the likelihood of emergency room visits was examined, children with 
private insurance plans had 28% lower likelihood of having an emergency room visit 
when compared to those who with public insurance (p<0.01).  African American and 
Hispanic children were (8% and 52% respectively, p<0.01) more likely to visit the ER 
department compared to White children. Patients who took more controller medication 
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were 47% less likely to visit the ER department than those who took more reliever 
medicationS (p<0.01).  Children with prior either event of hospitalization or event of ER 
visit were 24% more likely to have ER visits in follow up period (p<0.01). A unit 
Increase in total number of prescriptions was associated with 13% increase in likelihood 
of emergency room visit (p<0.01). The patients who had a prior outpatient visit were 61% 
less likely to have an ER visit than those who had not (p<0.05). When frequency of ER 
visits was examined, privately insured children has a lower frequency of an ER visit 
compared to publicly insured children (0.50, p<0.01). African American and Hispanic 
children were more (17% and 41%, respectively) likely to have the ER visits compared to 
White (p<0.05 and p< 0.01) children. Children who were seen by pediatricians had 61% 
less frequent ER visits (p<0.01). Unsurprisingly, higher asthma severity was associated 
with higher frequency of ER visits (1.28, p<0.01; 1.06, p<0.05). Patients who had visits 
to outpatient clinics were 55% less frequent ER visits (p<0.01).       
[Table 6.5 goes about here] 
 
Discussion 
This study provides the first comparison of pharmaceutical care and health care 
utilization and cost among publicly and privately insured children with asthma. We found 
that asthmatic children enrolled in Medicaid had significantly more likely to have an ED 
visit and inpatient hospital visits. Higher health care service utilization (ER visits and 
Hospitalization) by asthmatic children enrolled in Medicaid may reflect differences in 
quality of care because many of these children with asthma were not seen by specialists 
in spite of medical insurance.  Though the public insurance enrollees have access to a 
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medical home and other support mechanisms such as transportation and translation 
services, there was a notable disparity between the public and private insurance enrollees 
with regards to use of ER for pediatric asthma care. The higher use of ER for asthma 
related visits might be due to several reasons. The ER might be a regular source of care 
among the Medicaid enrollees or there might a failure on the part of the physicians and 
parents adhere to optimal asthma management practices for asthmatic children.  There is 
requirement of better coordination between the government, private payers, various 
physicians, facility providers and other stakeholders to reduce the unnecessary use of ER. 
The Aday Anderson model of healthcare utilization was used as the theoretical 
framework for this study. Only some of the variables from the model were significant 
predictors of asthma in children. Among the predisposing variables, age and 
race/ethnicity were considered to be significantly associated with ER visits and 
hospitalizations. Gender was not a significant predictor of either ER visits or 
hospitalization which indicates that gender is not relevant after fully adjusting for other 
factors.  The need factors in the model were measured using the well-validated asthma 
severity index. Disease severity was one of the need factors and children with higher 
asthma severity had a greater likelihood of having ER visits and hospitalizations.  One of 
the enabling factors was physician specialties. Our study showed that children who 
regularly had a pediatrician visit had a less likelihood of having ER visits and 
hospitalizations.   
This study has some limitations. First, the Marketscan Medicaid dataset did not 
allow the state identification so it was not possible to identify trends specifically by 
individual states. Also patient enrollment before the study period was not known which 
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might change the impact of managed care environment on the patients who had a longer 
exposure to the same.  A longer follow up time might have improved the models.  The 
time to event modeling technique was used which gave a more direct measure of the 
influence of time on asthma health outcomes. The frequency of short periods of 
disenrollment was more common in publicly insured population compared to privately 
insured population. This happened when the eligibility of publicly insured population 
expired or when they failed to meet recertification requirements on a timely basis.  The 
disenrollment period did not impact the average length of enrollment of the participants 
in the study but it was not possible to capture the source of care of the participants during 
the disenrollment. There might be loss of coverage due to actual change in eligibility 
status but continuity of care can be enhanced by reducing loss of coverage occurring 
because of administrative reasons.  
 Even though this study has several limitations, the study has some important 
implications for health care providers and policy makers. The delivery of healthcare 
among the publicly and privately insured enrollees is mainly associated with a SES 
disparity. This disparity in the delivery of healthcare is characterized by lost productivity 
in the workforce and higher medical costs resulting from untreated chronic conditions for 
a long time.  Even though concerns for equity in healthcare go beyond health care 
providers and health plans involved in case management, they too, to an extent, 
contribute to some of the disparities. Some physicians or facilities might show resistance 
towards changing the traditional methods of practice due to lack of motivation resulting 
from inadequate incentives to optimize treatment and services. Lack of incentives to 
provide quality care might also be one of the reasons. The financial incentives created by 
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the current financing mechanism in the US are being discussed in detail elsewhere.   In 
summary, there are no major incentives above and beyond financial incentives that 
motivate healthcare providers to make patients change their health providers. The 
improvement in quality brought about by providers and health plans is mainly driven by 
financial incentives. 
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Table 6.3 Patient Characteristics across the Health Plans 
 
Variables Measure 
Public 
(n=6435) 
N (%) / mean (SD) 
Private 
(n=4592) 
N(%)/ mean (SD) 
P-value 
Age in years 
Sex 
 
Race/ethnicity 
 
 
Visit to pediatrician 
Hospitalization 
ER visit 
Medication Possession Ratio  
MPR 
  <40% 
  <80% 
   >80% 
Asthma drug ratio > 0.50 
Severity Index  
   1  
   2 
   3 
Total number of prescriptions 
Number of outpatient visits  
Total Expenditure 
Continuous 
Male 
Female 
White 
Black 
Hispanic 
(yes/no) 
(yes/no) 
(yes/no) 
Continuous 
Categorical 
 
 
 
(yes/no) 
Categorical 
 
 
 
Continuous 
Count 
Continuous
8.1 (6.8) 
2469 (38.3%) 
3966 (61.7%) 
3192 (49.6%) 
2830 (43.9%) 
413 (6.5%) 
4956 (77.0%) 
2132 (33.1%) 
3761 (58.4%) 
40.11 (35.32) 
 
4839 (75.1%) 
1299 (20.1%) 
297 (4.6%) 
3549 (55.1%) 
 
2042 (31.7%) 
2171 (33.7%) 
2222 (34.5%) 
25.9 (22.9) 
8.9 (12.9) 
$11,075 (29,587) 
8.3 (7.1) 
2280 (49.6%) 
2312 (50.4%) 
2287 (49.8%) 
1565 (34.1%) 
 740 (16.1%) 
 3854 (83.9%) 
 1320 (28.7%) 
 1498 (32.6%) 
45.74 (31.52)  
 
2608 (56.7%) 
1446 (31.5%) 
538 (11.8%) 
3198 (69.6%) 
 
 1265 (27.5%) 
 1788 (38.9%) 
1539 (33.6%) 
12.8 (9.6) 
11.5 (10.6) 
$14,722 (35,276) 
0.365 
<0.01 
 
0.12 
 
 
<0.01 
<0.05 
<0.01 
<0.01 
<0.01 
 
 
 
<0.01 
<0.05 
 
 
 
<0.01 
<0.05 
<0.01 
*: p<0.05 **: p<0.01 
Severity index: 
1: No events,  
2: 15 or more beta- Agonist canisters or 1 or more filled prescriptions for oral corticosteroids,  
3: Hospitalization or Emergency Department encounters 
 
 
 
 
 
 
 
 
  130
Table 6.4 Comparison of Medication Adherence Rates across Health Plans 
  MPR – 40 % (quantile)  MPR – 80% (quantile) 
Variables  B (SE) 95% CI  B(SE) 95% CI 
Type of health plan    
  Public 
 Private 
Age group: 
1-4 
5-18 
Sex 
Male                              
Female                          
Race/ethnicity 
  White 
  Black 
  Hispanic 
Visit to pediatrician 
Asthma drug ratio  > 0.50 
Severity Index  
   1  
 2 
   3 
Total number of 
prescriptions 
Number of outpatient 
visits  
Total Expenditure 
Constant 
  
Ref 
3.30 (2.54) 
 
Ref 
1.13 (0.33)** 
 
Ref 
0.36 (2.02)* 
 
Ref 
0.05 (0.18) 
0.13 (0.05)* 
2.31 (0.78)** 
0.39 (1.28) 
 
Ref 
0.09 (0.69) 
0.21 (0.74) 
0.18 (0.28) 
 
-0.06 (0.05) 
 
0.03 (0.007)** 
6.44 (1.22) 
 
 
(-1.69, 8.29) 
 
 
(0.47, 1.79) 
 
 
(0.03, 0.76) 
 
 
(-0.31, 0.42) 
(0.02, 0.23) 
(0.77, 3.85) 
(-2.11, 2.91) 
 
 
(-1.25, 1.45) 
(-1.24, 1.67) 
(-0.38, 0.72) 
 
(-0.13, 0.08) 
 
(0.02, 0.04) 
(4.05, 8.84) 
  
Ref 
4.79 (0.95)** 
 
Ref 
4.94 (0.59)** 
 
Ref 
2.22 (0.46)** 
 
Ref 
-0.0002 (0.69) 
-2.43 (1.96) 
6.51 (0.94)** 
1.08 (0.31)** 
 
Ref 
-1.87 (2.19) 
0.07 (0.02)** 
-0.11 (0.02)** 
 
0.02 (0.01)* 
 
0.04 (0.004)** 
21.66 (2.77) 
 
 
(2.92, 6.66) 
 
 
(3.79, 6.11) 
 
 
(1.31, 3.13) 
 
 
(-1.36, 1.36) 
(-6.27, 1.41) 
(4.66, 8.35) 
(0.48, 1.68) 
 
 
(-6.18, 2.42) 
(0.01, 1.43) 
(-0.16, -0.07) 
 
(0.02, 0.02) 
 
(0.03, 0.06) 
(16.23, 27.09) 
Chow-test 
Asthma drug ratio and Private insurance 
F(4, 10801) = 46.14 P> F = 0.0000
*: p<0.05 **: p<0.01 
Severity index: 
1: No events,  
2: 15 or more beta- Agonist canisters or 1 or more filled prescriptions for oral corticosteroids,  
3: Hospitalization or Emergency Department encounters 
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Table 6.5 Comparison of Health Care Utilization across Health Plans 
OR 95% CI IRR 95% CI OR 95% CI IRR 95% CI OR 95% CI IRR 95% CI
Ref Ref Ref Ref Ref Ref
1.23** (1.02, 1.74) 1.42** (1.15, 1.75) 0.32** (0.16, 0.68) 0.80* (0.71, 0.91) 0.72** (0.41, 0.99) 0.50** (0.39, 0.65)
1-4 Ref Ref Ref Ref Ref Ref
5-18 2.12** (1.62, 2.64) 1.29** (1.04, 1.80) 1.04 (0.56, 1.75) 0.99 (0.63, 1.54) 1.21 (0.92, 1.66) 1.03 (0.81, 1.31)
Male Ref Ref Ref Ref Ref Ref
Female 1.32* (1.04, 1.69) 1.12 (0.96, 1.37) 1.89** (1.57, 2.36) 1.05* (1.01, 1.43) 1.31 (0.94, 1.79) 1.27 (0.67, 2.18)
White Ref Ref Ref Ref Ref Ref
Black 0.54** (0.28, 0.69) 0.63* (0.54, 0.97) 1.82** (1.21, 2.64) 1.04 (0.58, 2.23) 1.08* (1.01, 1.18) 1.17* (1.05, 1.28)
Hispanic 0.62** (0.49, 0.85) 0.76* (0.63, 0.98) 1.22** (1.09, 1.42) 1.52* (1.05, 2.09) 1.52* (1.05, 2.19) 1.41** (1.17, 1.69)
1.11 (0.93, 1.23) 1.09 (0.88, 1.55) 0.78** (0.55, 0.96) 0.91* (0.82, 0.99) 0.96** (0.93, 0.99) 0.39** (0.32, 0.48)
1.43 (0.47, 2.15) 1.16 (0.51, 1.63) 0.95* (0.86, 0.99) 1.01 (0.96, 1.05) 0.53** (0.39, 0.73) 0.77** (0.52, 0.99)
1.02 (0.84, 1.49) 0.95 (0.80, 1.12) 0.59** (0.34, 0.86) 0.82** (0.59, 0.91) 0.61** (0.31, 0.93) 0.88** (0.56, 0.99)
1 Ref Ref Ref Ref Ref Ref
2 1.09 (0.88, 1.36) 1.06 (0.86, 1.52) 1.15* (1.07, 1.25) 1.41* (1.05, 1.89) 1.92** (1.50, 2.45) 1.28** (1.15, 1.42)
3 1.29* (1.01, 1.69) 1.12* (1.01, 1.45) 1.72* (1.12, 2.63) 1.19 (1.09, 1.28) 1.24** (1.08, 1.42) 1.06* (1.02, 1.20)
1.22 (0.83, 1.58) 1.04 (0.89, 1.18) 0.95** (0.91, 0.99) 0.94 (0.76, 1.16) 1.13** (1.02, 1.25) 1.10** (1.05, 1.18)
1.28 (0.98, 1.53) 1.05 (0.93, 1.21) 0.62* (0.47, 0.79) 0.64* (0.49, 0.87) 0.39** (0.19, 0.63) 0.45** (0.33, 0.61)
0.99 (0.75, 1.22) 1.03 (0.81, 1.35) 1.05 (0.88, 1.26) 1.01 (0.89, 1.21) 1.06 (0.88, 1.29) 0.81 (0.66, 1.00)
Severity Index
Total # of Prescriptions
# of Outpatient visits
Total Expenditure
Variables
Age group
Sex
Race/Ethnicity
Visit to Ped. Doctor
Asthma drug ratio > 0.5
MPR 
Private
       Office visit Hospitalization ER visits
Type of health plan
Public
 
 
*: p<0.05 **: p<0.01 
Severity index: 
1: No events,  
2: 15 or more beta- Agonist canisters or 1 or more filled prescriptions for oral corticosteroids,  
3: Hospitalization or Emergency Department encounters 
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CHAPTER 7 
OVERALL CONCLUSION 
 
7.1 Major Findings of Studies 
The overarching topic of this research was to examine the effect of physician 
payment incentives on the medication-based outcomes in children with asthma. The study 
aimed to objectively examine some of the gaps in the current knowledge with regards to 
the potential effects of such incentives on physician prescribing and patient utilization, 
comparing effects in commercial and Medicaid plans to assist in the formulation of  
evidence-based  cost-effective asthma care for children in an era of growing needs for 
cost-containment and scarce resource access.  First, this study focused on trying to jointly 
understand the patterns of prescribing and access to controller/reliever medications for 
asthmatic children. Next the study focused on examining health care utilizations such as 
office visit, inpatient visit, and ER visits associated with the use of controller/reliever 
medications. Understanding how sociological factors including financial incentives affect 
physician prescribing behavior related to anti-asthmatic medications and in turn, pediatric 
medication adherence for anti-asthmatic treatments were some of the novel directions 
explored by this research. Assisting policy makers identify sources of variation in asthma 
healthcare while reducing underuse of treatment was the key objective of this research.  
The study results indicated and implied the following concerns and corresponding policy 
implications which are discussed below. 
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 First, significant disparities in Hispanic children were clearly noted in these 
studies with regards to both physician prescribing and patient utilization of anti-asthmatic 
medication. Hispanic children were less likely to receive the controller medication for 
asthma treatment compared to white children and also had poorer health care utilization-
related outcomes. Even though racial/ethnic health disparities have been documented 
substantially, effective policy interventions are still needed to deal with this issue of 
significant concern (such as medication therapy management and community health 
worker for special populations).  
 Second, reimbursement mechanism (Capitated vs. FFS) of Medicaid had a strong 
association with patients’ medication adherence as well as health care utilization. Our 
study indicated significant differences in anti-asthmatic medication adherence between 
capitated plans and FFS. The findings of this study showed that patients under the 
capitated plan had lower medication adherence compared to patients under the FFS.  
Patients enrolled in capitated plan were more likely to have limited prescription benefit 
for asthma, which one could potentially attribute to capitated plans providing a fixed 
dollar amount per member per month for all pharmacy services.  Thus study findings 
clearly implied that there were certain pediatric populations that might be at higher risk 
for improper health care due to type of insurance plans they were enrolled in. Thus 
findings reconfirmed that the mechanism of reimbursement in Medicaid could play an 
important role in asthmatic children’s access to appropriate pharmacotherapy.  
Third, health plans (public vs. private) had a strong association with patients’ 
medication adherence as well as health care utilization patterns in pediatric asthma. Our 
study highlighted significant differences in anti-asthmatic medication adherence between 
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publicly insured and privately insured children. Pediatric asthma patients enrolled in 
public insurance had lower medication adherence compared to patients under the private 
insurance. Asthma has well-developed, evidence-based clinical guidelines which requires 
structured behavior on the part of physicians, patients and their parents to manage it. 
According to asthma guidelines, asthma severity can be determined by regular physical 
check-up and monitoring patient history.  To control asthma, physicians are required to 
ascertain the degree of damage to tissues and loss of function in the relevant organ 
systems. Physicians should ensure that the patients are following asthma guidelines, 
getting the appropriate tests, having a routine follow up to monitor their asthma and are 
aware of asthma management strategies. Physicians might sometimes fail to follow the 
enlisted procedures due to a variety of reasons like lack of knowledge or appreciation of 
the importance of clinical guidelines, indifference or non-coverage on the part of health 
plans, short duration of patient visits due to low reimbursement from health plans and 
rising health care costs. Health plans also should extend their support towards physician’s 
efforts to encourage asthma management among patients. They can do so by offering 
training and performance feedback to physicians based on administrative records and 
chart reviews as well as reminder services to patients. However, the efforts of different 
health plans might vary and this might result in many missed opportunities to improve 
care. 
In summary, asthma management can be mandated by health plans by 
implementing the chronic disease model of care for asthma patients and patients with 
other ailing conditions. The services recommended by the asthma guidelines can be 
provided individually or in a group by nurses, respiratory therapies, or certified health 
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education specialists, provided it is being supervised by a physician. The important point 
is that the initiative should be collective and not individualized. 
 
7.2 Implications of Study results for Medicaid policymaking 
           The federal and state government holds the responsibility for managing the 
publicly funded health programs like Medicare and Medicaid. The framing of any health 
policy at the state or the federal level requires taking into account several factors like 
public cost, access to care and quality of care.  Generally, it is possible to achieve high 
quality if care and improve access to this care by increasing the budget required for 
financing the public healthcare programs. The additional costs pose an undue burden on 
the government. The challenge therefore is to achieve high quality of care and equal 
access with contained costs. The concept of chronic disease management as a means to 
cost containment is gaining popularity but the execution of the same needs an outlook 
that is lacking. 
The failure of the Medicaid to reduce asthma specific disparities over the time 
period of this study might be attributable to insufficient management of the condition in a 
managed care environment. More resources may need to be applied to case management, 
to an expanded asthma specialist networks, or to improved monitoring and feedback to 
physician regarding asthma care guidelines. The fact is that MCOs are limited in the 
quantity and quality of care they provide based the contracted price received from the 
state Medicaid. They are likewise constrained from providing too little quality and 
quantity of care by state.  Compared to FFS plans, children enrolled in capitated health 
plan had significantly lower medication adherence and significantly lower number of 
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outpatient visits. Lower medication adherence is associated with higher hospitalization 
and ER visits. Lower number of outpatient visits limits access to healthcare and 
continuous care for asthma. Though capitation is one of the techniques used most 
successfully to contain costs in the Medicaid population, study findings suggest that this 
might not be cost effective for long term asthma management among children. Children 
with asthma might have specific needs that need to be accounted for if the policy makers 
and the third party payers may need to facilitate better access to quality healthcare and 
improved medication adherence for optimum asthma management among children. 
  
7.3 Test of Theoretical Model 
As mentioned previously, the theoretical model of the study was based on the 
constructs of the Eisenberg and Aday-Anderson Model. The theoretical model is outlined 
in figure 2.3. We faced some limitations using the NAMCS dataset in terms of 
availability of variables and could not measure the influence of some of the physician 
behavior related constructs which are a significant part of the Eisenberg model such as  
the level of patient adherence and self-management behavior in the model associated with 
prescribing asthma pharmacotherapy medications. However, the influence of constructs 
like patient (age and race) and physician characteristics (specialty), and percentage of 
financial incentives could be determined. Our findings primarily suggest that Hispanic 
children might be at higher risk for sub-optimal asthma care validating that age and race 
are important predictors of asthma pharmacotherapy. Only some of the variables from the 
Aday-Anderson model were significant predictors of asthma health care utilization in 
children in our cohort. Among the predisposing variables, age and race/ethnicity were 
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found to be significantly associated with ER visits and hospitalizations. Gender was not a 
significant predictor of either ER visits or hospitalization which indicates that gender is 
not relevant after fully adjusting for other factors.  The need factors in the model were 
measured using a validated asthma severity index. Not surprisingly the study found that 
children with higher asthma severity had a greater likelihood of having ER visits and 
hospitalizations.  Another enabling factor was physician specialty, and this study showed 
that children who regularly had a pediatrician visit had a lower likelihood of both ER 
visits and hospitalizations.  In sum, the Eisenberg and Aday-Anderson models proved to 
be suitable models to develop our final framework for this study. However, further 
research should incorporate additional predictors which are suggested by these models. 
 
7.4 Limitations and Contributions 
There are several limitations of this study which deserve note. In our analysis of 
physician prescribing of anti-asthmatic medications we used a public access database the 
NAMCS which unfortunately, does not provide all the relevant physician and patient 
variables that are needed to test our theoretical model for the study influenced by the one 
proposed by Eisenberg (1979). Additionally there is no measure of clinical severity of a 
child’s asthma within the database; so we could not control for this when examining 
which children received an anti-asthmatic medication and what type of anti-asthmatic 
medication they received. Third, the database is based on self-report by physicians and 
their staff and so it is subject to some recall bias. Fourth, the database does not provide 
health care utilization (ER visit and Inpatient visit) details of the patient and the primarily 
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outpatient sample of visits could exclude severe cases of asthma who may not be seen in 
these settings. Finally, the database lacks specific variables that explain the impact of 
medication adherence and self-monitoring behaviors, as well as variables that measure 
barriers to physician guideline adherence. 
 For the second and third analyses, first, we could not examine geographical 
variations in utilization rates as specific states from which the sample was drawn were 
not identified. Thus we could not explore how eligibility requirements affect differences 
in study outcomes across the states. Additionally, like most studies that use claims data 
the final analytical datasets lacked specific clinical information that is only available from 
patient chart review or electronic medical records. As such, data concerning physician 
adherence to guidelines was incomplete, and patients’ severity of asthma and health 
beliefs was not explicitly measured. Therefore severity index scores calculated from 
claims in the pre-index period were used as a proxy for the severity of asthma. We 
attempted to control for sample selection using multivariate analyses, but we could be 
limited in this approach because of insufficient variable detail. Administrative data can 
also suffer from data entry errors or omissions that can be difficult to detect or evaluate. 
Medication adherence calculations from the claims dataset assume that patients utilize all 
the medications that are being dispensed to them. The medication adherence rate does not 
provide direct information about the medication utilization by a patient but provides an 
estimate of the maximum possible medication utilization. MPR also fails to capture 
medication utilization characteristics of inhaler medications like timeliness, prescribing 
directions and consistency of medications. Hence it is possible that the prescribed 
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medication might be used with more or less frequency which might over estimate or 
under estimate medication adherence (Erickson 2001). 
 Even though the study has several limitations, these limitations do not overweigh 
the contribution of this study. Previous literature had not explored the impact of the type 
of health plan (based on financial incentive) on medication adherence behavior. This 
study provided insight about the impact of capitated health plans versus traditional FFS 
plans on the pharmacological treatment of asthma in children. Study results could help 
policy makers design appropriate reimbursement policies that ensure effective allocation 
of scarce healthcare resources among vulnerable population. Also, previous literature 
lacked evidence about the effect of different health plans on the medication adherence 
outcomes of asthmatic children. None had evaluated differences in pharmaceutical 
outcomes between asthmatic children in Medicaid and privately insured children for the 
same time periods. Additionally, study results provide fairly comprehensive and 
concurrent information regarding Medicaid and commercial insurance related-care in 
asthmatic children and relevant recent trends in pediatric asthma health care utilization.  
 In sum, the results of this study provide an insight to clinicians, policymakers and 
health service researchers in evaluating policies related to insurance coverage of essential 
medications in indigent children with asthma. Also, it helps in differentiating among 
medication adherence outcomes and health care utilization with respect to different 
payment mechanisms or health plans in asthmatic children in the United States. This, in 
turn, could help understand important factors that impact health care financing, design 
strategies to improve asthma related care, and improve health outcomes for needy and 
poor children in the United States. 
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7.5 Future Research 
Although this study explored important issues related to insurance coverage and 
pharmaceutical care in pediatric asthma care in the US, there are several topics in this 
field that require further research. First, future research needs to focus on health policy 
evaluation in specific cost constrained environments [such as pay for performance (P4P) 
in Medicaid] related to health care reform. Additionally future studies need to better 
highlight healthcare outcomes across socio-demographic variants in truly underserved 
areas in the United States such as rural Appalachia. Finally, future studies need to 
emphasize comparative effectiveness research (explicitly comparing treatment 
alternatives for their effectiveness in asthma) using techniques such as meta-analyses, 
geospatial analyses and instrumental variables.          
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